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Plasticizers are added to polymeric materials to increase flexibility and durability, 
thus they constitute a common, and widely used class of industrial chemicals. Plasticizers 
have been suspected of a number of adverse health effects including the interference with 
the endocrine system.1 These substances have the tendency to migrate to the surfaces of 
materials, where they can be absorbed, ingested, or inhaled. 5 The iniquitousness of 
plasticizers and the daily contact with polymeric materials has given rise to concern about 
the toxicity and health effects of these substances. Many long-term and excessive-dose 
studies have been conducted on many of these chemicals, but little has been done to 
determine the short-term and small-dose effects of these types of compounds. 2,3,4 
Classical methods of examining the biodistribution of such substances include 
autoradiography, as well as an array of other analytical techniques. While these methods 
can sufficiently provide biodistribution data, they suffers some limitations.  
The majority of this thesis will argue that positron emission tomography (PET) is 
a potential replacement for classical techniques to monitor biodistribution and 
pharmacokinetics of widespread environmental contaminants. The work in this masters 
  
thesis is focused on the preparation of three labeled model compounds: [18F] 2-fluoro-4-
(2-(4-hydroxyphenyl)propan-2-yl)phenol, [18F] diethyl 4-fluorophthalate, and [18F] bis(2-
ethylhexyl) 4-fluorophthalate. Imaging of these compounds will be offered as proof of 
principle. Studies demonstrate that this approach is feasible, and that it can complement 
and replace many of the laborious animal studies used in current toxicology research.   
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CHAPTER 1 
Tools to Measure Biodistribution 
1.1 Introduction 
Plasticizers are added to polymeric materials to increase flexibility and durability, 
thus they constitute a common, and widely used class of industrial chemicals. These 
substances have the tendency to migrate to the surfaces of materials, where they can be 
absorbed, ingested, or inhaled. 5 The iniquitousness of plasticizers and the daily contact 
with polymeric materials has given rise to concern about the toxicity and health effects of 
these substances.  One key element in evaluating the toxicity of a substance is to study its 
pharmacokinetics and biodistribution in animals and humans. There are several classical 
methods of measuring biodistribution. The majority of this thesis will argue that positron 
emission tomography (PET) is a potential replacement for classical techniques to monitor 
biodistribution and pharmacokinetics of widespread environmental contaminants. The 
work in this masters thesis is focused on the use three labeled model compounds: [18F] 2-
fluoro-4-(2-(4-hydroxyphenyl)propan-2-yl)phenol, [18F] diethyl 4-fluorophthalate, and 
[18F] bis(2-ethylhexyl) 4-fluorophthalate. Imaging of these compounds will be offered as 
proof of principle. Studies demonstrate that this approach is feasible, and that it can 
complement and replace many of the laborious animal studies used in current toxicology 
research.   
1.2 Classical Methods of Measuring Biodistribution 
Many classical techniques exist for measuring the absorption, distribution, 
metabolism and elimination (ADME) of a given substance.  Some studies give 
information about exposure to circulating metabolites, identity of metabolites, rate at 
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which metabolites are excreted, and the route of elimination.  Other studies have the 
ability to characterize the distribution of a compound/metabolites in a given tissue or 
organ sample at one given time point. 
The most useful tool for measuring adsorption, distribution and metabolism is 
coupled gas chromatography and mass spectrometry. In its simplest form, GC/MS is used 
to evaluate the concentrations of a given substance in a bodily fluid or tissue. GC/MS 
analysis of multiple samples withdrawn at serial time points can provide an exceptionally 
accurate picture of the time course of the concentration profile in vivo. As an example, 
Hong-xia and co-workers used GC/MS to identify the active compound of a Chinese 
herbal medicine, Gastrodia elata Blume, and measure its biodistribution in mice. The 
animals were fed this compound, then urine and brain samples were collected. These 
samples were treated with acetic anhydride to enhance the volatility of the compound and 
its metabolite(s) and then injected into a GC/MS, which separated and identified the 
acetylated derivatives. 6  
Other methods have also been utilized to monitor biodistribution of a given 
compound including gas chromatography-mass spectrometry (GC/MS), (liquid 
chromatography- mass spectrometry (LC/MS), and mass spectrometry- mass 
spectrometry (MS/MS).  Frias et. al. developed a GC/MS/MS method that was able to 
detect chlorocarbon pesticides in human serum samples, and Smeds and Saukko used 
GC/MS to measure these substances in adipose tissue.7 The U.S. Center for Disease 
Control and Prevention (CDC) developed a high-throughput LC/APCI-MS/MS (Liquid 
chromatography/atmospheric pressure chemical ionization-mass spectrometry/mass 
spectrometry) to quantify eight phthalate metabolites in human urine.7  The urine samples 
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were processed using enzymatic deconjugation of the glucuronides, followed by 
LC/APCI/MS/MS analysis. This method allowed for rapid detection of phthalate 
metabolites with relatively low detection limits. The CDC later further optimized this 
study by incorporating an isotopically labeled (13C) internal standard for each of the eight 
analytes as well as a conjugated internal standard to monitor deconjugation efficiency 
In absorption, distribution, metabolism and excretion (ADME) studies, it is 
common to radiolabel a compound in order to track it and its metabolites at the tracer 
level. In these cases, a variety of MS and GC instruments coupled to on- or off-line 
radioactivity detection can be employed. [14C] Carbon and tritium, both beta-emitting 
isotopes, are commonly used for this type of analysis because their incorporation leads to 
virtually no change in the molecular structure or properties of the target compound.   An 
example of the instrumentation used to measure radioactivity in an ADME study would 
be HPLC-MS/radiometry, which combines both radiochromatographic profiles for 
isotope quantification with mass spectral data of metabolites of a radiolabeled parent 
compound.8  
 MS-based techniques can provide information regarding identification, 
concentration and isotopic ratios in serum samples, but still suffer some limitations.  
These methods tend to require more work to obtain appropriate standards. Moreover, the 
extraction efficiency and characterization of various matrix effects on quantitation must 
be evaluated for each organ or tissue sample.9 For MS samples, the compound needs to be 
ionized, which can cause different responses from metabolites than that of the parent 
compound. This creates a challenge for adequate quantification of specific metabolites 
and requires preparation of synthetic standards and calibration curves for each ion source. 
17 
 
10
 Most importantly, these techniques do not allow for direct visualization of 
biodistribution and binding of a given substrate in real time.  In many cases, excretion 
and serum samples and animal sacrifice must be performed at various time points to 
retrieve complete information of adsorption, distribution, and metabolite quantification 
and qualification. 
Autoradiography is another widely used tool to monitor the biodistribution of 
radiolabeled compounds. It has the benefit of permitting visualization of the distribution 
and binding of targets at various time points. This technique is used to localize 
radioactivity within a solid specimen, which provides data on distribution of a given 
substance and can ultimately assess whether a substance can be completely eliminated or 
not. In an autoradiography study, a subject can be sacrificed after injection of a 
radiolabeled ligand (in vivo autoradiography) or a target organ or tissue can be examined 
after treatment with a radiolabeled ligand (in vitro autoradiography). In either case, the 
collection of tissue samples is conducted by freezing the whole animal or organ and 
cryosectioning the subject. After treatment with the radio-ligand, these tissue sections are 
then exposed to a photographic emulsion or a phosphoimaging device that detects and 
quantifies the radioactivity in selected tissues. 10 The radionuclides of choice are typically 
[3H] tritium (β decay), [14C] carbon (β decay) or [125I] iodine (γ decay).  A typical dose 
supplied in vitro is around 160 µCi/kg. 8 In order to gather information about distribution, 
a statistically valid number of animals are injected with the same compound, and at least 
three at a time are sacrificed at each time point to determine biodistribution and 
pharmacokinetics. 
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While autoradiography can provide data on biodistribution, this method has a 
number of limitations. First, studies have shown that the use of tritium and iodine-125 as 
radioisotopes can be problematic in autoradiography analysis. Tritium has the tendency to 
undergo hydrogen exchange with water, and in many cases 125I is not biologically benign 
in vivo and has shown to be liberated from the parent compound. 8,9 The extent of 
dissociation limits the accurate interpretation of the autoradiograph. The generation of 
carbon-14 can be difficult and time consuming. It requires labor-intensive operations to 
convert 14C to graphite and is not readily adaptable to automation. This results in low 
throughput sample preparation and high cost analysis.8 Therefore, many researchers often 
use 3H or 125I.  Autoradiography is also limited by its inability to decipher between parent 
molecule, metabolites or degradation product, as it only detects total-substance 
radioactivity.8 Finally, autoradiography does not allow for multiple time points to be 
observed in a single subject, rather at each time point, at least three subjects will be 
sacrificed. Thus, this technique cannot be applied for assessing ADME in human trials. 
In summary, many experimental methods exist to monitor distribution of a 
compound in vivo. The above-mentioned methods have the capability of efficiently and 
accurately providing information on identity, substrate concentration, binding targets, 
metabolism and elimination.  However, the major limitations of these methods warrant 
the need of a technique that allows for non-invasive, visualization of biodistribution over 
a series of time points in a single test subject. More recently, positron emission 
tomography has become increasingly popular in ADME studies because it is a less 
invasive technique, and can give an abundance of information relating to biodistribution 
and pharmacokinetics on a single, living subject.  My research focuses on the application 
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of PET as a method to assess the distribution and toxicological profile of three industrial 
used plasticizers: bisphenol A, diethyl phthalate, and bis (2-ethylhexyl) phthalate.  These 
compounds were selected as test cases for assessing PET as a standard tool in 
environmental toxicology, because there exists a wealth of data derived from classical 
biodistribution, pharmacokinetic, and pharmacodynamics studies. 
 
1.3 Positron Emission Tomography 
Positron Emission Tomography (PET) is a valuable, non-invasive nuclear 
imaging technique that allows for the visualization of physiological and biological 
processes in vivo in real time. While PET is commonly used for diagnostic confirmation 
and tumor localization, it is also useful as a means to determine pharmacokinetics and 
pharmacodynamics of early phase pharmaceuticals.  PET holds advantages over methods 
like autoradiography, as it allows for the visualization of biodistribution in real time, and 
it also permits these measurements on a single subject at multiple time points.  Also, the 
non-invasive nature of PET permits this method to be used in human studies, which is 
why tracer studies are commonly conducted for many pharmaceutical drugs before they 
enter Phase II or Phase III trials. 8  
PET has the potential to supplant classical methods such as autoradiography. 
Autoradiography is limited is its ability to also monitor kinetics, and multiple subjects 
must be used to get usable data for distribution studies.  When using multiple subjects, 
there is much room for error.  Different subjects may react differently to a compound, 
depending on sex, weight, blood type, etc. On the other hand, PET provides the 
investigator with the ability to perform multiple scans at various time points on a single, 
 living subject. This allows for more accurate kinetic studies as well as fu
of the biodistribution of a compound.  Figure 1
autoradiography and PET for the assessment of Alzheimer’s patients
utilized [18F]-labeled THK523
the brain. Figure 1-1A show
Alzheimer’s disease.11 Figure 1
a 72-year-old woman who was diagnosed with Alzheimer’s disease.
same information can be drawn from a PET scan as from an autoradiogram, but PET can 
be conducted on a living patient to 
kinetics, distribution and binding of a specific compound over time.
A)   
Figure 1-1: Comparison of autoradiograph
patients. A) Autoradiogram of [
[18F]THK523 binding to 
-1 depicts a comparison of 
, a compound that recognizes and bind to tau proteins
s the hippocampus of a 90-year-old woman who died of 
-1B are PET scans of three different levels of t
12
assess the efficiency of treatments, and monitor 
  
  B) 
 
 and PET scan of Alzheimer’s Disease 
18F]THK523 binding to tau tangles.11 B) PET scan of 
tau proteins. HC: healthy control; AD: Alzheimer’s disease
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PET imaging is performed after
that is labeled with a positron emitting 
kinetic energy positron is emitted, which, upon slowing down, captures 
cause an annihilation.  This phenomenon releases two
180° from each other. The coincident 
detector that surrounds the patient. This co
A.    
Figure 1-2: A) A representation of a positron
phenomenon that occurs.
the emitted gamma rays 
Various radionuclides can be
PET agents, as seen in Table 1
interest because carbon is
isotopic substitutions with a radioisotope of carbon does
A significant advantage of
 injecting a patient with a radiopharmaceutical
radionuclide. As the radionuclide
 511 keV gamma rays 
λ-rays are detected by a circular 
ncept is illustrated in Figure 1-
        B. 
          
-emitting nucleus and the annihilation 
 Adapted from Z. Li, 2010.13  B) A diagram of the detection of 
by a scintillator. Adapted from C. West, 2004
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 contained in all organic compounds, and thus it is b
 not affect biodistribution
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21 
  
 decays, a high 
an electron and 
oriented at 
scintillation 
2.   
 
.
14
 
 to be used as 
on molecules of 
elieved that 
 in vivo.  
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This short half-life means that the total radioactive dose given to the patient can be quite 
small. However, the short half-life poses a significant problem for the radiochemist; 
elaborate syntheses are typically ruled out. In contrast, using a radioisotope with a much 
longer half-life, such as [124I] iodide (t ½ =4.18 d), the disadvantage is that dosimetry is 
less favorable.  Of the nuclei mentioned in Table 1-1, [18F] fluoride is the most useful to 
monitor short-term biodistribution. Advantages include: 1) a reasonable half-life of 109.7 
minutes. This permits injection of the radiolabeled drug, a number of scans at various 
time points, and clearing of the radioactivity to occur in one day. 2) This radionuclide 
also has low positron energy (0.64 MeV) resulting in a relatively short range in tissue 
(maximum 2.2 mm) permitting high-resolution images.  3) 18F-Fluoride can be produced 
in large amounts (>10 Ci) in a cyclotron, and 4) has acceptable radiation dosimetry for 
multiple studies in a patient.15 Aryl florination of pharmaceuticals offers many 
advantages, which can include enhanced solubility, bioavailability and metabolic stability 
compared to non-fluorinated analogues.19 
Isotope Half-life Decay 
Mode 
Eβ+ avg. 
[KeV] 
Maximum (avg) 
range in water 
[mm] 
Max. Specific 
Activity [Gbq 
µmol-1] 
11C 20.39 min. β+ (99.8%) 
EC (0.24%) 
385 3.8 (1) 3.4*105 
13N 9.96 min. β+ (99.8%) 
EC (0.2%) 
491 5.0 (1.5) 7.0*105 
15O 122.24 sec. β+ (99.9%) 
EC (0.01%) 
735 7.6 (2.7) 3.4*106 
18F 109.77 min. β+ (96.73%) 
EC (3.3%) 
242 2.2 (0.3) 6.3*104 
124I 4.17 d. β+ (22.8%) 
EC (11.0%) 
188 9.7 (3) 1.2*103 
 
Table 1-1: Commonly used radio-nuclei for PET and their properties. [Adapted from 
Browne and Firestone (1986) and Brookhaven National Laboratory, Internet database, (2003).] 
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  Aqueous [18F] fluoride is produced by proton bombardment of a 18OH2 target (p+ 
+ 18O  18F + n). The [18F] fluoride so produced is solvated with water, which reduces its 
nucleaphilicity. To overcome this problem, [18F] fluoride is trapped on an ion exchange 
resin to remove excess water and eluted with an aqueous solution of bicarbonate. To 
enhance the nucleophilicity and solubility of fluoride, the potassium ions are complexed 
by a cryptand, typically 1,10-diaza-4,7,13,16,21,24-hexaoxabicylco[8.8.8]hexacosane 
(Kryptofix 2.2.2) as shown in Figure 1-3. Water is removed by azeotropic distillation 
with a hydrophilic polar solvent, such as acetonitrile. Once the 18F anion is dry, its 
nucleophilicity is enhanced so then it can participate in nucleophilic substitution reactions 
and related chemistries. 
 
1.4 Methods of Fluoride Incorporation 
 Several methods are currently employed to incorporate 18F-fluoride into aromatic 
compounds.  Nucleophilic aromatic substitution (SNAr) typically utilizes an “F -“ source, 
such as tetramethyl ammonium fluoride (TMAF), tetrabutyl ammonium fluoride (TBAF), 
or Kryptofix 222 KF. A significant limitation of nucleophilic aromatic substitution is that 
the reaction occurs only in electron poor systems. In cases where electron-withdrawing 
groups are not present in the final product, multistep syntheses are required to transform 
or remove an “activating” group. 
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Figure 1-3: Structure of Kryptofix 222 KF, used in radiofluorination. 
  
Direct electrophilic aromatic substitution utilizes an “F+” source such as NFSI16, 
Selectfluor17, or NFOBS.16, 18 This approach works reasonably well for electron rich 
arenes, but regioselectivity is sometimes an issue.19 To conduct electrophilic reactions 
with 18F, the synthesis of 18F2 is generally required. This is a difficult reagent to prepare 
and handle routinely. In addition, its preparation involves dilution with 19F. Use of this 
“carrier added” reagent leads to low specific activity compounds and the need to inject a 
significant amount of the imaging agent.  This is a major limitation if highly potent 
compounds are being radiolabeled.  
 Another approach to incorporate fluoride into an arene is to employ a metal ion or 
main group atom fluorination reaction.  The general mechanism for a metal catalyzed aryl 
fluorination is illustrated in Figure 1-4.  This method can tolerate a variety of functional 
groups, but suffers from several constraints.  Foremost among these is that the precursors 
are somewhat air-sensitive and unstable.   
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of the synthesis and reductive elimination of diaryliodonium salts is shown in Figure 1-5. 
This illustration shows the two possible routes to prepare diaryliodonium salts that are 
used in our laboratory. First, an iodinated substrate can be oxidized to the hypervalent 
I(III) species, which is then coupled to a trifluoroborate arene to form a diaryliodonium 
salt. Alterntively, the desired substrate can be modified to a potassium trifluoroborate 
salt, which is then couple to a hypervalent I(III) arene to form a diaryliodonium salt.  In 
both cases, TMS-X serves as a trimethyl silyl ligand to activate the I(III) center. These 
TMS-X groups act to “tune” the electrophilicty of the I(III) center, thus, the reaction can 
be “customized” for either electron poor or electron rich systems.  In the DiMagno group, 
many TMS-X catalysts are used including TMS-TFA (trimethylsilyl trifluoro acetate), 
TMS-OTf (trimethylsilyl triflate) and TMS-OAc (trimethylsilyl acetate). 
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Figure 1-5: The synthesis and reductive elimination of diaryliodonium salts. A) A 
hypervalent I(III) substrate is coupled to a trifluoroborate arene to form a diaryliodonium 
salt. B) Trifluoroborate modified substrate is coupled to a hypervalent arene to form a 
diaryliodonium salt.  C) Reductive elimination of an aryl iodide from a diaryliodonium 
fluoride to form a fluoroarene. 
 
1.5 Conclusions 
Classical methods of measuring biodistribution provide valuable information but 
still suffer from some limitations. PET imaging is potentially a complementary technique 
to visualize the distribution, adsorption and metabolism of compounds of interest. Unlike 
toxicokinetic measurement methods driven by GC/MS instruments, PET alone cannot 
identify and distinguish among metabolites. While PET can supplant such methods as 
autoradiography, methods to detect various metabolites will still be need to be utilized for 
biodistribution and toxicity studies. While there are multiple routes to incorporate 18F 
onto a desire substrate for PET, for this work, the synthesis of a diaryliodonium salt 
precursor of diethyl phthalate, bis(2-ethylhexyl) phthalate and bisphenol A are explored 
for proof of principle studies.  Once the diaryliodonium precursors are in hand, then 
biodistribution studies can be conducted to assess the efficiency of PET as a valuable, 
non-invasive tool for evaluating environmental toxicology of widely used industrial 
chemical. 
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CHAPTER 2 
Diethyl Phthalate 
2.1 Introduction 
 Diethyl phthalate (DEP) is a commonly used plasticizer. DEP is primarily used as 
a solvent or in cellulose acetate polymers. Unlike heavier chain phthalate esters, DEP is 
not used as a plasticizer in PVC because its low molecular weight makes it somewhat 
volatile. In 2008, approximately 5,200 of the 5,800 metric tons of consumed diethyl 
phthalate produced in the U.S. were used in cellulose acetate polymer formulations. 
These materials were used in films, tool handles and adhesives. 23 In 2010, the EPA 
reported that DEP was also found in a variety of other products including soaps, 
detergents, adhesives, sealants, rubber, and plastic products.  DEP has also been found in 
cosmetics, epoxy resins, pharmaceutical and personal care products, children’s toys, and 
insect repellents. DEP is also a component in fragrances.23 The large number and variety 
of products in which DEP is found mean that consumers encounter this compound from 
multiple products on a daily basis. Moreover, this exposure to diethyl phthalate can occur 
through dermal absorption, inhalation and ingestion.  
Diethyl phthalate exposure and the biodistribution of this compound in animals 
and human subjects are measured using the classical methods described in Chapter 1. The 
overall goal of this research is to develop an alternative, positron emission tomography 
(PET) based methodology to track this compound in vivo. The immediate goal of this 
project was to synthesize a diaryliodonium triflate precursor, which could be readily 
radiofluorinated to yield 4-[18F]-fluorodiethyl phthalate.  This radiotracer will be 
evaluated to determine if the behavior of the fluorinated compound exhibits comparable 
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biodistribution and pharmacokinetics compared to the nonfluorinated material. If so, 4-
[18F]-fluorodiethyl phthalate will be offered as a means to visualize the in vivo 
biodistribution of this environmental contaminant in real time. 
 
2.2 Known Metabolism of Diethyl Phthalate 
 The major pathway of diethyl phthalate metabolism is hydrolysis to the 
monoester, which can be further hydrolyzed to phthalic acid or glucuronidated. Oxidation 
of the ester side chain also occurs as is outlined in Figure 2-1.24 Hydrolysis of DEP 
occurs in the lumen of the gastrointestinal tract, in intestinal mucosal cells, or in the liver, 
kidneys and lungs after systematic absorption.25   
Several studies have used 14C-labeled DEP to monitor the biodistribution and 
metabolism of the parent compound.  In 1976, Ioku and co-workers fed 14C-labeled DEP 
to rats and mice and assessed its biodistribution by autoradiography at 48 hours post 
administration.  The kinetics of the tissue distribution of DEP was also measured, and it 
was found that maximum radioactivity (at 20 minutes post administration) was found in 
the kidneys and liver, followed by blood, spleen and fat.23, 25 The concentration of 
radioactivity was measured in excretion samples and it was found that there was a rapid 
decrease to trace amounts after 24 hours. Excretion was found to occur primarily through 
the kidneys; only about 3% of the total administered dose was elimination in feces.  The 
authors identified two main metabolites: monoethylphthalate (MEP) (major) and phthalic 
acid (minor). This early study proves that DEP is cleared rapidly from rodents. This fact 
was used to argue that a single bolus of administered DEP carries little long term 
exposure risk. 
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A second study of the biodistribution of DEP in male rats probed the impact of 
dermal application of [14C] DEP (5-8 mg/cm2). Urine and fecal samples were collected 
and analyzed by liquid scintillation spectrophotometry every 24 hours for 7 days.26 It was 
noted that 24% of the total dose was excreted within 24 hours. After animal sacrifice, 
radioactivity was detected in the brain, lungs, spleen, small intestines, kidneys, testis, 
blood and spinal cord, but each having a concentration less that 0.5% of the administer 
dose.  It was noted that 86% of the given dose remained on the surface of the skin. This 
indicates that dermal absorption of DEP is very slow. This finding is significant 
considering that human exposure to DEP primarily occurs through application of 
fragrances and body lotions on the skin.  
 
 
Figure 2-1: Pathways for metabolism of diethyl phthalate (DEP). 
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An experiment in 1975 by Singh and co-workers, monitored [14C] diethyl 
phthalate in serum following intraperitoneal injection into 13 pregnant rats at either day 5 
or day 10 of gestation. Analysis of withdrawn serum samples by liquid scintillation 
spectrophotometry showed that the distribution of radioactivity in maternal blood peaked 
at 24 hours then diminished quickly. A similar pattern was seen in fetal tissue and 
amniotic fluid. The rate of elimination was found to fit a first-order excretion curve.  It 
was also suggested that radioactivity from the radiolabeled compound was transmitted 
through the placenta into the fetus. The [14C] radioactivity was widely distributed and 
detected in maternal blood, amniotic fluid and the fetus (all <1%) at all gestational time 
points that were investigated.24 This study is significant in that it shows that the mother 
and the fetus are both exposed to DEP, but it is also eliminated quickly from both the 
mother and fetus.  Again, this suggests that prolonged exposure to DEP, even when 
administered by injection, is minimal.   
 The specific enzymes that are responsible for the hydrolysis of DEP have not yet 
been completely characterized for various species. However, DEP has shown to be 
hydrolyzed to the monoester by purified carboxylesterases isolated from human and rat 
liver. In 1987, Ashour et. al. demonstrated that microsomal carboxylesterase activity 
toward DEP was induced in mouse liver and rat kidneys.25  Some major enzymes that are 
involved in the microbial metabolism of DEP include phthalate oxygenase, phthalate 
dioxygenase, phthalate dehydrogenase and phthalate decarboxylase.27, 28, 29 In a study 
performed with commercially available porcine and bovine pancreatic cholesterol 
esterase (CEase, EC 3.1.1.13), it was found that DEP was hydrolyzed to MEP within 24 
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hours.30 In 1997, Kayano and co-workers found that a novel esterase, ES46.5K,  isolated 
from mouse hepatic microsomes demonstrated strong hydrolytic effects toward DEP and 
other short chain phthalate esters, but was less effective at hydrolyzing longer chain 
derivatives such as bis(2-ethylhexyl) phthalate (DEHP).31 This esterase hydrolyzed only 
one of the ester groups of DEP; formation of phthalic acid was not observed even after 
prolonged incubation.  From a study in 1998 by Hotchkiss and co-workers it was 
demonstrated that skin could also hydrolyze DEP to MEP using in vitro percutaneous 
absorption with rat and adult human skin. There are a variety of enzymes responsible for 
the metabolism of DEP and they are found in several areas of the body. All of these 
studies mentioned in this section confirm the efficient metabolism and rapid clearance of 
DEP from the body.  
 
2.3 Potential Health Effects of Diethyl Phthalate 
 While there is an industrial demand for diethyl phthalate, some studies of human 
populations have suggested that its widespread use could be cause for concern.  Diethyl 
phthalate and its commonly found metabolite, monoethyl phthalate (MEP) are found in 
population samples at levels often orders of magnitude greater than those of other 
phthalates such as bis (2-ethylhexyl) phthalate (DEHP) and di-n-butyl phthalate (DBP).32 
The prevalence of DEP in personal care products and its volatility, are thought to be 
responsible for the relatively elevated exposure to this compound. 
 Studies in animals and humans suggest that exposure to DEP may be responsible 
for a number of reproductive issues, especially in males.  In dose-response studies 
performed by Duty (in 2003) and Hauser (in 2007) it was shown that damage to sperm 
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DNA was associated with high levels of MEP in urine samples in two groups of adult 
human males that were undergoing tests for infertility.3 In 2005, Jonsson and coworkers 
evaluated urine, serum, and semen samples from 234 young Swedish males and found 
that men with the highest concentrations of MEP experienced 8.8% fewer sperm, 8.9% 
more immotile sperm, and lower serum luteinizing hormone values compared to men 
with lower levels of MEP.3 However, the results of these studies were questioned because 
no data were reported for the actual exposure (amount or duration) to DEP each man 
experienced. 
  There are several other studies that correlate serum or urinary DEP metabolites to 
health effects. One of these was a 2005 study by Swan and co-workers reporting a 
significant association of MEP in samples in pregnant women with age-adjusted 
anogenital index (AGI) of postnatal males at 2-36 months of age. AGI, which describes 
the span of the perineum, the portion of the body between the anus and genitalia, has 
been suggested as a tool for identifying male sexual development vs. male feminization. 
It was concluded that MEP concentrations had an inverse relationship with AGI.33 In a 
study in 2007, Stahlhut and co-workers correlated phthalate exposure with abdominal 
obesity and insulin resistance in adult males in the US.  It was shown that MEP level was 
significantly associated with increased abdominal circumference and increased insulin 
resistance.26 MEP is also suspected of being hepatocarcinogenic and teratogenic in mice 
who experience chronic exposure or administration of a large dose.31 Again, these studies 
show that there may be a correlation between higher DEP metabolites in urine and serum 
samples and a shortened AGD in male offspring, obesity, diabetes and liver cancer. 
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However, it is difficult to give a definitive answer as to if DEP is indeed the cause of 
these health problems considering there was no record of the administered doses of DEP. 
Several research studies have appeared in which accurate accounting of DEP 
exposure was recorded. In 1993, Jones investigated organelle changes in Leydig cells of 
rats that were exposed to four different phthalates including diethyl phthalate in a gavage 
dosage of 2000 mg/kg body weight once a day for two days.24 Administration of DEP 
resulted in mitochondrial swelling, smooth endoplasmic reticulum focal dilation and 
vesiculation, and increased interstitial microphage activity associated with surface of the 
Leydig cells of rats. These data provide evidence that very large doses of DEP may be 
potentially damaging at the cellular level; however, the dose given is large that the 
relevance of these results on human exposure to DEP is questionable. 
While earlier studies provided evidence suggesting that the dermal absorption of 
DEP was modest and slow, the National Toxicology Program (NTP) conducted a study 
observing the effects of dermal exposure to DEP over the course of 4 weeks. DEP was 
applied dermally to B6C3F1 mice at doses of 12.5, 25, 50, and 100 µL (approximately 
560, 1090, 2100 or 4300 mg/kg for males and 630, 1250, 2500 or 5000 mg/kg for 
females) 5 days/week. It was found that dermal application of undiluted DEP resulted in 
increased relative liver weight in mice.25 Intriguingly, this study showed that adverse 
effects (increases in absolute and relative liver weights) only occurred in female test 
subjects.  In another 4-week study performed by the NTP, DEP was applied to the skin of 
F344/N rats (200, 400, 800 or 1600 mg/kg for males and 300, 600, 1225, or 2500 mg/kg 
for females, given 5 days/week). This study showed increased relative liver weights in 
the higher dosed males and females.25 These data suggest that prolonged exposure to 
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DEP at relatively high-doses could have a negative effect on the liver. Again, these doses 
and long-term exposure are not comparable to human exposure levels.  
In summary, the above studies indicate there may be a correlation between DEP 
exposure and adverse health effects.  DEP is suspected to be associated with sperm 
damage, shortened AGD in male offspring from mothers that were exposed during 
pregnancy, obesity, insulin resistance, and possible liver cancer. However, there was no 
reported data on the amount or duration at which those studied had been exposed to.  
Nonetheless, there are data suggesting that prolonged exposure to DEP in relatively high 
doses can have adverse effects toward rat livers and can be detrimental to organelles in 
rat cell lines.  
I am interested in preparing a [18F]-labeled DEP derivative to enable monitoring 
of the biodistribution and pharmacokinetics of DEP in mice using positron emission 
tomography (PET). [18F]-DEP would be administered at a nanomolar concentration and 
assessed at various time points to verify if DEP or its metabolites are binding to any 
receptors in the body or if there is any evidence that this compound could be responsible 
for the speculated adverse health effects at relatively low doses, comparable to that of 
human daily exposure. 
 
2.4 Synthetic Approach  
The synthetic approach that was used to prepare the diethyl phthalate 
diaryliodonium salt and fluorinated analogue is illustrated in Scheme 2-1 below.  The 
first step was to oxidize commercially available 4-iodoxylene to 4-iodophthalic acid 
following the methods proposed by Dudič.34 Several esterification methods, including 
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thionyl chloride and ethanol resulted in mixtures that contained significant amounts of the 
monoester product. While the desired product could be readily separated from these 
reaction mixtures, it was found that esterification of 4-iodophthalic acid with N,N'-
dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP) and ethanol 
provided an enhanced yield of the desired diester. Simple filtration through silica gel was 
sufficient to obtain the desired starting product in good yield and purity.  
 
 
Scheme 2-1: Synthetic scheme of the synthesis of diethyl phthalate diaryliodonium 
triflate salt and conversion to the fluorinated analogue. 
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Once 4-iododiethyl phthalate was isolated, it was oxidized with Selectfluor and 
TMSOAc in dry acetonitrile.  Proton NMR spectroscopy was used to follow the 
progression of the oxidation reaction. After optimization of the reaction conditions, it was 
found that maximum conversion to the aryliodonium diacetate intermediate occurred at 
24 hours at 60 °C.  Once formed, the I(III) intermediate was treated with potassium 
trifluoro(4-methoxyphenyl)borate and TMS-OTf to form the diaryliodonium salt 
precursor.  The desired product was easily purified by washing the solid product with 
methyl-tert-butyl ether (MTBE). Sonication of the mixture was used during the washing 
step to assist the removal of impurities that might be trapped in the solid matrix of the 
product.  
High specific activity radiochemical syntheses generate vanishingly small amounts 
of material. In fact, standard UV-visible detectors on analytical HPLC equipment are 
insufficiently sensitive to detect the amount of radiotracer prepared be the methods we 
use in our group. Therefore, a “cold” fluorination standard sample of every compound 
must be prepared to help the radiochemist establish the identity of the radiolabeled 
product. The first preparation of the standard used a model reaction of the radiosynthesis: 
the diaryliodonium salt precursor was treated with 0.8 equivalents of 
tetramethylammonium fluoride (TMAF) in dry acetonitrile for about 15 minutes to effect 
an ion exchange and prepare the corresponding diaryliodonium fluoride. The solvent was 
removed and replaced with dry C6D6 and the mixture was heated at 120 °C for 10-20 
minutes. It was found that the optimal temperature and time needed for maximum 
conversion was 20 minutes at 120°C. The final product was analyzed by HPLC (275 nm 
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UV detection, mobile phase: 65% acetonitrile : 1% acetic acid in water, Phenomonex, 
Luna, C18 column). The HPLC trace of the isolated standard is given in Figure 2-2.  
 
 
Figure 2-2: HPLC trace of 4-fluorodiethyl phthalate. 
 
2.5 Conclusions 
In summary, diethyl phthalate is a widely utilized industrial chemical that can be 
found in everyday consumer items such as soaps, detergents, sealants, fragrances, lotions 
and plastic products, such as children’s toys. Routes of exposure to DEP include dermal 
absorption, ingestion, and inhalation. Diethyl phthalate has been reported to metabolize 
and eliminated from the body quickly. The metabolism of DEP is mainly through 
hydrolysis to the monoester, which can be hydrolyzed to phthalic acid or glucuronidated. 
Ethyl side chain oxidation products are also formed. While it has been reported to 
metabolize rapidly, the widespread use of DEP by consumers, can correlate to having a 
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high concentration of DEP or its metabolites in urine and serum samples. DEP has been 
speculated of being responsible for a number of adverse health effects, as mentioned 
above. While there may be evidence of DEP metabolites present in many of these studies, 
there was little evidence that DEP was solely responsible for many of the conditions 
discussed, or the DEP doses were incredibly large. It is also unclear why males would be 
more susceptible to DEP than female subjects. 
The focus of this project was to prepare the diaryliodonium triflate salt precursor, 
which could be exposed to late-stage radio-fluorination to yield [18F] 4-fluoro-diethyl 
phthalate. The radiotracer could then be injected into a test subject at nanomolar 
concentrations and visually assess the biodistribution in real time using PET.  This could 
give vision to where diethyl phthalate is going through the body at reasonable 
concentrations. PET scans can also give insight to if there is any occurrence of target 
binding that may be associated with these speculated health effects, however other 
qualification tests would need to be conducted to know to what extent, and to where, 
exactly, a compound is binding. 
 
2.6 Experimental Data 
 
 
 
4-iodophthalic acid  
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This is a known compound (CAS 6301-60-6) but was synthesized according to the 
procedure reported by Dudič.34 In a 1L round bottom flask, 4-iodo-1,2-dimethylbenzene ( 
11.0 mL, 77.4 mmol) was diluted in160 mL of pyridine. Potassium permanganate (146.7 
g, 928.8 mmol) and 340 mL of deionized water were added and the reaction mixture was 
allowed to reflux for 72 hrs. After the mixture cooled to RT, the reduced manganese salts 
were removed by filtration, and the filtrate was acidified carefully with concentrated 
hydrochloric acid to pH 1-2. Upon acidification, a white precipitate was formed and 
extracted with ethyl acetate. Extraction of the reaction mixture with ethyl acetate 
followed by evaporation of the solvent in vacuo produced a light pink solid. The crude 
product was dissolved sodium carbonate, and the aqueous solution was washed with ethyl 
acetate (3 X 50 mL). The aqueous solution was adjusted back to pH=1 with concentrated 
hydrochloric acid, precipitating the purified product. The mixture was extracted with 
ethyl acetate and the solvent was removed under reduced pressure and dried in vacuo to 
yield 9.70 g (43%) of the colorless product. 1H NMR (D2O+CH3CN, 400 MHz, 25°C) δ 
8.26 (d, J= 1.6, 1H), δ 8.12 (dd, J1= 1.6, J2= 8.2, 1H), δ 7.68 (d, J= 8.2, 1H); 13C NMR 
(D2O+CH3CN, 100 MHz, 25°C) δ 170.4, 169.7, 140.8, 137.7, 133.8, 131.1, 130.8, 98.1; 
HRMS (ESI): Calcd C8H5O4I [M-H2O]+ 274.9205; found 274.9173. 
 
 
Diethyl-4-iodophthalate  
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This compound is known (CAS 67193-51-5) but was prepared using the esterification 
reaction modeled after that used by Buchwald.74 In a 250 mL round bottom flask, 4-
iodophthalic acid (2.32 g, 7.94 mmol) was dissolved in 15 mL of dichloromethane.  
Ethanol (0.93 mL, 15.9 mmol) and DMAP (0.24 g, 1.96 mmol) was added to the reaction 
flask, which was cooled to 0 °C. N,N'-dicyclohexylcarbodiimide (DCC) (3.44 g, 16.7 
mmol) was dissolved in 10 mL of dichloromethane and added to the cooled reaction 
mixture in a drop-wise fashion.  The reaction was stirred and allowed to warm to RT 
slowly for 12 hours.  A white precipitate had formed as a result of an insoluble DCC by-
product, DCU, which was filtered off of the reaction mixture.  The filtrate was stirred for 
an hour with hexanes, producing more DCU solid, which was removed by filtration. The 
filtrate was subjected to reduced pressure removing the solvent and the desired product 
was purified by column chromatography (5% EtOAc: Hexanes).  After removal of 
solvent, 2.13 g of a clear oil was obtained in a 77% yield. 1H NMR (CD3CN, 400 MHz, 
25°C) δ 8.04 (d, J= 2.0, 1H), 7.96 (dd, J1= 8.0, J2= 1.6, 1H), 7.47 (d, J= 8.0, 1H), 4.30 (q, 
J= 7.2, 2H), 4.29 (q, J= 7.2, 2H), 1.31 (t, J= 7.2, 3H), 1.30 (t, J= 7.2, 3H); 13C NMR 
(CD3CN, 100 MHz, 25°C) δ 167.7, 166.9, 141.2, 138.3, 135.1, 132.4, 131.4, 98.0, 62.9, 
62.8, 14.4; HRMS (ESI): Cald C12H13IO4 [M+Na]+: 370.9756; found 370.9774 
 
[3,4-Bis(ethoxycarbonyl)phenyl]-(4’-methoxyphenyl)iodonium triflate 
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In a N2 charged atmosphere, in an oven dried Schlenk flask, diethyl-4-iodophthalate (2.08 
g, 5.98 mmol) was dissolved in 60 mL of dry acetonitrile. In a 20 mL scintillation vial, 
Selectfluor (2.75 g, 7.76 mmol) was dissolved in 10 mL of dry acetonitrile, followed by 
trimethylsilyl acetate (2.33 mL, 15.5 mmol) that was diluted in 10 mL of dry acetonitrile 
and was allowed to mix for 3-5 mins. The Selectfluor solution was added to the 
reaction mixture in a drop-wise fashion. This mixture was sealed and stirred at 60 °C for 
24 hrs. In a inert atmosphere, potassium trifluoro(4-methoxyphenyl)borate (1.28 g, 5.98 
mmol) was dissolved in a minimal amount of dry acetonitrile and added to the reaction 
flask. In a 20 mL scintillation vial, trimethylsilyl trifluoromethanesulfonate (1.0 mL, 5.8 
mmol) was diluted in 10 mL of dry acetonitrile and added to the reaction flask in a drop-
wise fashion.  The flask was sealed and reacted at RT for 12 hours. The solvent was 
removed under reduced pressure. The mixture was dissolved in dichloromethane and 
washed with deionized water (3 X 50 mL). The organic layer was dried over sodium 
sulfate, and upon removal of the solvent produced a colorless solid.  The solid was 
ultrasonicated in methyl-tert-butyl ether (3 X 50 mL) and dried in vacuo. The resulting 
white solid was subjected to a triflate ion exchange column (Amberlite IRA-450 (OTf)) 
in a solution of acetonitrile/water (80:20). The solvent was removed under high dynamic 
vacuum overnight. This resulted in 2.67 g (73%) of a colorless solid.  1H NMR (CD3CN, 
400 MHz, 25°C) δ 8.37 (d, J=1.6 Hz, 1H), 8.21 (dd, J1= 2.0, J2= 8.4, 1H) 8.05 (d, J= 9.2, 
2H) 7.75 (d, J= 8.4, 1H) 7.07 (d, J= 9.2, 2H) 4.32 (q, J= 7.2, 2H) 4.32 (q, J= 7.2, 2H) 3.84 
(s, 3H), 1.31 (t, J= 6.8, 3H) 1.30 (t, J= 6.8, 3H); 13C NMR (CD3CN, 100 MHz, 25°C) δ 
167.0, 165.8, 164.6, 139.1, 138.6, 137.1, 135.9, 135.5, 132.9, 119.3, 118.4, 116.8, 102.6, 
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63.5, 63.4, 56.8, 14.3, 14.3; 19F NMR (CD3CN, 376 MHz, 25°C) δ-80.9.  HRMS (ESI): 
Cald C20H20F3O8IS [M-OTf]+: 455.0356; found 455.0366.  
 
Diethyl 4-fluorophthalate  
This compound is known (CAS 320-96-7) but preparation by this route has not been 
previously reported. In an N2 charged glove box, diethyl 4-((4-
methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-λ3-iodanyl)phthalate (0.3 g, 0.5 mmol) 
and tetramethyl ammonium fluoride (0.04 g, 0.40 mmol) was dissolved in dry acetonitrile 
(15 mL) in a 50 mL Schlenk tube.  The solution was allowed to stir at room temperature 
for 5 minutes and the solvent was evaporated under high dynamic vacuum.  The reaction 
mixture was then dissolved in dry benzene (15 mL) and heated to 120 °C for 20 minutes. 
The solvent was evaporated and the product mixture was purified by column 
chromatography (5:95; Ethyl acetate: Hexanes). This yielded a clear oil (0.07 g) in 72% 
yield.  1H NMR (CD3CN, 400 MHz, 25°C) δ 7.81 (dd, 3JH-H= 8.6, 4JH-F= 5.4, 1H), 7.41 
(dd, 3JH-F= 8.9, 4JH-H= 2.5, 1H), 7.33 (td, 3JH-F= 8.4, 3JH-H= 8.4, 4JH-H= 2.5, 1H) δ 4.31 (q, 
J= 7.2, 4H), δ 1.32 (t, J= 7.2, 3H) δ 1.31 (t, J= 7.2, 3H); 13C NMR (CD3CN, 100 MHz, 
25°C) δ 167.5 (d, 4JC-F= 2.2 Hz) 167.2, 164.9 (d, 1JC-F= 251 Hz), 136.6 (d, 3JC-F= 8.1 Hz), 
132.8 (d, 3JC-F= 8.9 Hz), 129.0 (d, 3JC-F= 3.5 Hz), 118.9 (d, 2JC-F= 21.9 Hz), 116.8 (d, 2JC-
F= 24.3 Hz), 63.0, 62.7, 14.4, 14.4; 19F NMR (CD3CN, 376 MHz, 25°C) δ -109.03 (td, 
3JH-F= 8.6 Hz, 4JH-F= 5.4Hz); HRMS (ESI): Cald C12H13FO4 [M+Na]+: 263.0696; found 
263.0692. 
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CHAPTER 3  
Bis(2-ethylhexyl) phthalate 
3.1 Introduction 
 Bis(2-ethylhexyl) phthalate, commonly referred to as di(2-ethylhexyl) phthalate 
or DEHP,  is common plasticizer that has had a wide range of uses.  This colorless liquid 
has an aqueous solubility of 41 µg/L at room temperature. It is miscible with mineral oil 
and liquid hydrocarbons, such as hexane.  According to a 1999 report from Mannsville 
Chemical Products Corporation, 95% of DEHP is used as a plasticizer for polyvinyl 
chloride (PVC) products to induce flexibility.2 Examples of these PVC products include 
floor tiles, upholstery, wall coverings, shower curtains, swimming pool liners, garden 
hoses, plastic toys, rainwear, packaging film and sheets, and sheathing for wire and 
cables.  DEHP is also widely used in medical tubing, blood storage bags, disposable 
medical examination gloves, surgical gloves, and dialysis tubing.2 Less commonly, 
DEHP is used as a plasticizer in natural and synthetic rubbers. Non-plasticizer uses of 
DEHP include acting as solvent in erasable inks, as an acaracide in orchards, pesticides, 
and as an ingredient in cosmetics, vacuum pump oil ingredient, and dielectric fluids. It 
has also been used to detect leaks in respirators and for testing air filtration systems.   
DEHP can enter the environment through disposal of industrial and municipal 
wastes, and by leaching into consumer products that have been stored in material 
containing DEHP.  This compound has been shown to sorb strongly to soil and sediment.  
The most frequent route of exposure to humans is through ingestion.2 However, the 
greatest risk of acute exposure to DEHP occurs during medical procedures such as blood 
transfusions (estimated upper bound limit of 8.5 mg/kg/day) and hemodialysis (estimated 
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upper bound limit of 0.36 mg/kg/day).2 According to the U.S. Food and Drug 
Administration (2001) it was proposed the DEHP can leach from these plastic medical 
equipment into biological fluids and then into the patient.2 Due to an increase in the 
awareness of potential health concerns associated with DEHP, many companies have 
discontinued use of this phthalate.2 
It is important to note that the presence of DEHP in commonly used analytical 
equipment makes it difficult to accurately measure the relatively low levels of the 
compound in laboratory samples.  The ubiquitous nature of DEHP can lead to false 
positives during assays, and also introduce significant uncertainty in the amount of DEHP 
contaminant present.  
The focus of this project was to synthesize a diaryliodonium triflate precursor of 
bis(2-ethylhexyl) phthalate for the purpose of preparing radiolabeled DEHP. Once 
prepared, the radio-fluorinated DEHP analogue shall be administered to laboratory 
animals, and the pharmacokinetics and biodistribution of the compound will be measured 
using positron emission tomography (PET). 
 
3.2 Known Metabolism of Bis(2-ethylhexyl) phthalate 
 The metabolism of bis(2-ethylhexyl) phthalate is much like that of diethyl 
phthalate. The main metabolite detected in urine and serum samples is the corresponding 
monoester, MEHP, which can undergo further hydrolysis to phthalic acid or aliphatic side 
chain oxidation. The metabolic pathways for degradation of DEHP are illustrated in 
Figure 3-1 below. DEHP is more lipophilic than MEHP and it should readily absorb in 
the gastrointestinal tract. However, a 1980 study by White and co-workers indicated that 
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only the monoester was adsorbed in the small intestines of rats.35 This finding suggested 
the presence of a hydrophilic barrier in the lining of the small intestine that limits the 
amount of the parent compound being absorbed. Another report by Sjoberg and co-
workers in 1986 suggested that absorption of the orally administered dose of DEHP is 
age-dependent.36 This study showed that younger rats had the ability to absorb more 
MEHP through the small intestine than older rats when administered 2.7 mmol of DEHP/ 
kg/ day. 
  
Figure 3-1: Metabolic pathway of DEHP. 
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Bis(2-ethylhexyl) phthalate is hydrolyzed to MEHP and 2-ethylhexanol in the 
gastrointestinal tract by the combined actions of pancreatic lipase and an intestinal 
mucosa lipase.2 Other lipases, found in the liver, kidney, lungs and plasma have been 
reported to hydrolyze DEHP to MEHP.37 A small amount of MEHP is further hydrolyzed 
to phthalic acid while the remainder undergoes ω- and ω-1-oxidation of the aliphatic side 
chain.37 The products of ω-oxidation can undergo α- or β-oxidation, reducing the number 
of carbons in the side chain. The oxidized metabolites can also be glucuronidated and 
excreted. In a study performed on two humans in 1985, Schmid and Schlatter 
administered 30 mg of DEHP orally to two human volunteers and analyzed urine samples 
by mass spectrometry.38 From the metabolites in Figure 3-1, it was found that 20% was 
2-ethyl-5-oxyhexyl phthalate (VI), 30% was 2-ethyl-5-hydroxyhexyl phthalate (IX) and 
30% was 2-ethyl-5-carboxypentyl phthalate (V) of the total excreted material. MEHP 
accounted for up to 12% of excreted DEHP metabolites; the remaining metabolites 
accounted for less than 5% of the total excreted material.  
It has been suggested that similar metabolic pathways are involved when DEHP is 
inhaled or dermally administered due to the lipases present in alveolar cells and the 
epidermis. In 1989, Elsisi and co-workers administered a dermal dose of 30 mg/kg/day 
for 7 days to rats.26 Only 5% was excreted (3% in urine and 2% in feces) and 95% was 
recovered from the skin surface. This study demonstrated that transdermal absorption of 
DEHP was not extensive, suggesting that skin exposure is of relatively little concern.  
Secondly, the fact that 40% of the absorbed portion was found in the feces reflects the 
importance of biliary excretion.2  
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Other enzymes are responsible for further hydrolysis and oxidation of MEHP. For 
the hydrolysis of the monoester to phthalic acid, an esterase (primarily microsomal) is 
implicated.  MEHP can be reversibly glucuronidated, with the formation of the 
glucuronide catalyzed by UDP-glucuronyltransferase (Figure 3-1).  Regeneration of the 
aglycone, from the glucuronide, is catalyzed by β-glucuronidase. Oxidation of MEHP to 
the primary and secondary hydroxyl products is catalyzed by NADPH-dependent 
microsomal monooxygenases in a manner analogous or identical to fatty acid ω- and (ω-
1) hydrolases.37 Albro has postulated that the hydroxylated products are substrates for 
alcohol dehydrogenase, which produce aldehyde-containing metabolites. These 
compounds can be oxidized to di-acids by aldehyde dehydrogenase and NAD. The 
diacids can be further oxidized to form shorter acids with the help of α- and β-oxidation 
enzymes, cofactors, mitochondria and/or peroxisomes.37  
Because medical procedures significant exposure to DEHP, several studies were 
conducted to analyze the metabolism of intravenously administered plasticizers.  When a 
single dose of 14C-DEHP was administered intravenously to rats, the majority of the dose 
was recovered in the urine and feces, indicating that the major excretory pathways for 
rats were urine and bile.2 In 1975, Rubin and Schiffer demonstrated that humans who 
were administered a bolus of DEHP during a blood transfusion showed rapid clearance of 
the compound from the blood.39 Patients receiving an injection of platelets stored in a 
vinyl plastic pack displayed an initial DEHP plasma concentrations ranging from 0.34 to 
0.83 mg/dL. These concentrations decreased rapidly; the mean rate of DEHP clearance 
was 2.83% per minute and the plasma half-life of the compound and related metabolites 
was 28 minutes.  
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3.3 Potential Health Effects of Bis(2-ethyhexyl) Phthalate 
 In a study of prematurely born infants who required mechanical ventilation, it was 
found that the infants displayed unusual lung function similar to that of hyaline 
membrane disease, which is caused by insufficient surfactant production in the lungs.2 In 
1991, Klimisch and co-workers exposed rats to 1,000 mg/m3 of DEHP aerosol for 6 
hrs/day, 5 days/week, for 4 weeks and found evidence of increased lung weight, 
thickening of aveolar septa and proliferation of foam cells in male rats.40 These effects 
were found to be reversed 8-weeks post exposure. The female lab subjects did not display 
any of these symptoms. There are also reports that suggest that DEHP in house duct work 
can be responsible for the onset of asthma, wheezing, and eczema.32 
 The toxicity of DEHP itself is presumed to be low, but several of its monoester 
metabolites are presumed to exhibit toxicity. Oral ingestion of DEHP is associated with a 
number of health effects. While no direct human studies were located, Barry and co-
workers observed a potential human cardiac muscle contractility effect in an in vitro 
study in 1990.41 The monoester of DEHP, MEHP, displayed a dose-dependent negative 
inotropic effect of human atrial trabecule. This work suggests that high MEHP serum 
levels could lead to cardiotoxic effects in humans.  However, because of the rapid 
metabolism and excretion of MEHP, the long-term exposure to this metabolite would be 
minimal.  
In 2009, a study was conducted with clinically relevant concentrations of DEHP 
on neonatal rat cardiomyocytes.42 It was found that applying DEHP to a confluent, 
synchronously beating cardiac cell network, caused a loss of gap junction connexin-43, a 
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gap junction protein necessary for many physiological processes such as depolarization 
of cardiac muscles and the conducted response in microvasculature. This led to a marked, 
concentration-dependent decrease in conduction velocity, which is the speed at which an 
electrochemical impulse propagates down a nerve pathway. This ultimately caused the 
cells to beat out of sync. This experiment also showed that DEHP affected the 
mechanical movement of myocyte layers, which resulted in a decrease of triton-insoluble 
vimentin, leading to stiffness of underlying fibroblasts. 
 Experiments on rats and mice reported that liver mass increased in response to 
DEHP oral administration.  DEHP triggered rapid cell division along with some liver cell 
enlargement.2 Morphological changes caused by DEHP include fat deposits to the 
periportal area, a decrease in centrilobular glycogen deposits, and structural changes in 
the bile ducts. Hepatic cell enlargement and fat deposits are indicators of cellular lipid 
peroxidation.2 It has also been noted by Mitchell and co-workers that rats exposed to 50 
mg/kg/day of DEHP show an increase in hepatic peroxisomes in the centrilobular and 
periportal areas of the liver, which ultimately leads to cellular hypertrophy.43 These 
changes were only observed in male rats, even up to doses of 200 mg/kg/day, indicating 
that male rats are more susceptible to the hepatotoxic effects of DEHP than females. The 
reason why males are more susceptible is unclear. 
 DEHP is a well-known peroxisome proliferator. Peroxisomes are organelles that 
utilize molecular oxygen to produce hydrogen peroxide during the catabolism of a 
substrate.  Peroxisomal fatty acid oxidation follows the same pathway utilized by 
mitochondria, with the exception that ATP is not produced and hydrogen peroxide is 
produced in place of water. There are several studies that indicate that the activity of the 
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enzymes responsible for fatty acid catabolism is increased in rodents up to 1,500% after 
exposure to DEHP in doses greater that 11 mg/kg/day and longer than 2 weeks.2 When 
peroxisomal catabolism of fatty acids is not accompanied by an increase of the liver 
detoxifying hydrogen peroxide, the excess hydrogen peroxide can begin to react with 
cellular lipids, proteins, and nucleic acids. Marker of lipid reactions with peroxides, 
namely, lipofuscin deposits, were identified in high-dose studies in rats through their 
lifetime.44 These data suggest that some hepatic damage caused by DEHP can be 
attributed to the reaction of excess hydrogen peroxide with cellular lipids. 
 When studies were conducted on the endocrine effects of DEHP in rats, it was 
found that, in some cases, thyroid structure and activity were altered.  In 1986 when 
Hinton orally exposed male rats with 2,000 mg/kg/day for as little as 3 day, there was a 
significant decrease in serum thrytoxine (T4) levels at all time points observed.2 Electron 
microscopy also revealed a considerable increase in the number and size of lysosomes, 
signs of mitochondria damage and enlargement of the Golgi apparatus.  These 
ultrastructural changes are consistent with hyperactivity of the thyroid. These results are 
consistent with a study done in 2009 by Ghisari and co-workers.1 In this report, in vitro 
studies were conducted on thyroid hormone-dependent GH3 cells and MVLN cells 
derived from human breast cancer cells for estrogen receptor binding. Here, the thyroid 
hormone disrupting potential of DEHP was determined by the effect on the TH-
dependent rat pituitary GH3 cell proliferation and the estrogenic activity was assessed in 
MVLN cells, transfected with an estrogen receptor (ER) luciferase reporter vector.   
 Several rodent studies suggest that the testes are primary target tissues for DEHP 
in doses beyond 100 mg/kg/day.  Many of these studies reported decrease in testicular 
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weight and tubular atrophy, along with weight reductions for seminal vesicles, 
epididymis, and prostate gland.2 In a study from Albro and co-workers in 1989 45, acute 
testicular atrophy occurred when a single dose of DEHP (2.8 g/kg) or MEHP (0.8 g/kg) 
were orally given to young male rats and to testicular cells for in vitro studies. When 
testicular cells were subjected to 14C-labelled MEHP (8 µM), it was found that the cells 
could not metabolize MEHP beyond slight hydrolysis to phthalic acid after 24 hours.  
Sjoberg also suggests that MEHP, the metabolite of DEHP, is responsible for these 
testicular effects.36 There is also evidence from multiple rat studies that indicate sperm 
DNA damage and sperm malformations.2 
 There are few data on the effects of DEHP on female fertility. In a short-term 
study feeding female rats 140 mg/kg/day for 126 days resulted in a complete loss of 
fertility.46 When the rats were sacrificed, a significant decrease in the weights of ovaries, 
oviducts and uterus in females, as well as a decrease in sperm concentration and an 
increase in testicular atrophy in males was observed. These data suggest that DEHP had 
adverse effects toward reproductive organs in rats. In 1994, Davis and co-workers 
reported a decrease in serum estradiol levels, an increase in FSH levels and the absence 
of LH surges, which is necessary for ovulation, when given a one-time dose of 2,000 
mg/kg. This led to hypoestrogenic anovulatory cycles and the development of polycystic 
ovaries in female rats.47 
There are a plethora of studies on potential developmental effects caused by 
DEHP exposure, but only a few will be mentioned.  In 2005, Swan and co-workers 
conducted a study examining the anogenital distance (AGD) and other genital 
measurements on humans in relation to prenatal exposure to phthalates.33 It was found 
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that the oxidized metabolites of DEHP were those responsible for shortening of the AGD. 
A report from Colón in 2000, correlated phthalate metabolites in serum with pre-mature 
breast development in Puerto Rican girls younger than 8 years old with no other signs of 
puberty displayed.48 In this study several phthalates were screened and the monoester of 
DEHP accounted for 68% of phthalate metabolites present.   
 Bis(2-ethylhexyl) phthalate is noted to reduce fetal testosterone, and insulin-like 
growth factor-3, which results in male reproductive abnormalities in humans.  These 
abnormalities include shortened AGD, and malformations of the epididymis, vas 
deferens, semina lvesciles, and prostate, along with signs of hypospadias and 
cryptorchidism.32 These are all symptoms of a condition that has come to be named the 
“phthalate syndrome.” 
 The Carcinogen Assessment Group of the Environmental Protection Agency 
(EPA) classified DEHP as “probable human carcinogen”. When examining for 
carcinogenic potential it was found that the 2-ethylhexyl moiety is associated with 
hepato-carcinogenic activity in rodents.2, 49 In several chronic, high-dose feeding studies, 
it was noted that there was a clear dose-dependent increase in the appearance of liver 
tumors, and in some cases pancreatic islet cell adenomas were also observed.2  
 
3.4 Synthetic Approach 
The synthetic route to prepare the bis(2-ethylhexyl) phthtalate diaryliodonium 
triflate is depicted in Scheme 3-1 below.  Initially, the esterification reaction to form 
bis(2-ethylhexyl) 4-iodophthalate was conducted in the same manner as 4-iododiethyl 
phthalate with DCC, DMAP and 2-ethylhexanol (Scheme 3-2). In this reaction, the DCC 
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by-product formed, dicylcohexylurea (DCU), typically precipitates out of the 
dichloromethane solvent.  
 
Scheme 3-1: Synthetic route to prepare [3,4-bis(((2-ethylhexyl)oxy)carbonyl)phenyl]-
(4’-methoxyphenyl)iodonium triflate 
 
Scheme 3-2:  Initial route explored to synthesize bis(2-ethylhexyl) 4-iodophthalate. 
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Multiple filtration, precipitations, and column chromatography was not efficient to 
remove the residual DCU, as indicated in the 1H NMR in Figure 3-2.   
 
Figure 3-2: 1H NMR data representing the presence of DCU (indicated by red arrows) 
after column chromatography. 
 
To solve this problem, a second, a DCC-free esterification method was developed. 
4-Iodophthalic acid was treated with thionyl chloride to form 4-iodophthaloyl chloride. 
The thionyl chloride was removed and the resulting solid was dissolved in 
dichloromethane and treated with 6 equivalents of 2-ethylhexanol and pyridine in 
dichloromethane to form the desired diester in 12 hours. (Scheme 3-3). An aqueous 
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workup followed by solvent removal under high dynamic vacuum left the product 
contaminated with residual pyridine and excess alcohol, which were observed by 1H 
NMR. The reaction mixture was subjected to column chromatography in 100% hexanes, 
which removed the pyridine but not the residual alcohol. An aliquot was heated to 45 °C 
and stirred under high dynamic vacuum for 12 hours.  There was no observable change in 
the ratio of alcohol to product following this treatment. Further heating (60 °C for 2.5 
days) resulted in significant decomposition.   
Esterification of 4-iodophthaloyl chloride was also performed with triethylamine 
in chloroform as was reported by Navarro.50 The amount of alcohol used was also 
reduced to 2.2 equivalents. Unfortunately, when reduced amounts of the alcohol were 
used, a mixture of mono- and di-substituted products was obtained. 
 
Scheme 3-3: Esterification route from the di-acyl chloride species with modifications of 
the amount of 2-ethylhexanol used and various conditions (A &B). 
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While each of the prior esterification methods suffered from significant problems in 
product isolation and purification, the method of Kelber and co-workers 51 provided the 
desired product in sufficient purity. In this route, 4-iodophthalic acid was dissolved in 
acetonitrile and treated briefly with 1, 8-diazabicyclo[5.4.0]undec-7-ene (DBU) under an 
inert atmosphere before 2-ethylhexyl bromide was added. After the mixture was heated to 
95 °C for 14 hours, it contained a large amount of the desired ester with a minimal 
amount of the mono-substituted analogue. These products were easily separated from 
each other and from residual 2-ethylhexyl bromide by column chromatography.  The 
bis(2-ethylhexyl) 4-iodophthalate so isolated (62%), was treated with Selectfluor and 
TMSOAc, the general oxidation conditions developed in our laboratory, to provide bis(2-
ethylhexyl) 4-(diacetoxy-λ3-iodanyl)phthalate.  This I(III) intermediate was coupled with 
potassium trifluoro(4-methoxyphenyl)borate, using TMSOTf as a catalyst to provide 
[3,4-Bis(((2-ethylhexyl)oxy)carbonyl)phenyl]-(4’-methoxyphenyl)iodonium triflate, the 
DEHP diaryliodonium triflate salt, which was obtained as a paste-like compound that 
proved to be difficult to recrystallize. Despite the luck of crystallinity of this 
diaryliodonium salt, I decided to forge ahead with model fluorination studies. A sample 
of [3,4-Bis(((2-ethylhexyl)oxy)carbonyl)phenyl]-(4’-methoxyphenyl)iodonium triflate 
(0.30 g) was treated with 0.8 equivalents of TMAF in 15 mL of acetonitrile, evaporated, 
then dissolved in benzene and heated form 20 minutes at 120 °C.  This reaction produced 
the I(I) species, bis(2-ethylhexyl) 4-iodophthalate, along with the desired fluorinated 
DEHP, bis(2-ethylhexyl) 4-fluorophthalate and 4-iodo-anisole (Scheme 3-4). When this 
reaction was conducted on an NMR scale (0.02 g) and treated with 0.8 equivalents of 
TMAF, formation of the iodophthalate was still observed.  Because of the lack of 4-
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fluoroanisole as a major by-product, it was determined that “aryl-swapping” could be 
occurring at 120°C.   
 
 
Scheme 3-4: Fluorination reaction with 0.8 equivalents of TMAF with DEHP OTf salt. 
 
The suggested mechanism for aryl swapping for DEHP can be seen in Scheme 3-5, 
based on a report by DiMagno.52 This article reports that at 80°C in benzene, these aryl-
exchange products can be observed, and even more so at higher temperatures.  This could 
have been a result of an impurity in the triflate salt, thus recrystallization conditions for 
the triflate salt were explored.  
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Scheme 3-5: A) Possible aryl exchange products when subjected to fluoride anion. B-D) 
decomposition products for each scenario. 
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Another fluorination route was investigated utilizing commercially available 4-
fluoro-o-xylene, which was oxidized to 4-fluorophthalic acid. The product was esterified 
in the same fashion as mentioned above for bis(2-ethylhexyl) 4-iodophthalate in good 
yield (Scheme 3-6). This fluorinated standard was analyzed by HPLC (275 nm UV 
detection, mobile phase: 100 % acetonitrile, Phenomonex, Luna, C18 column). The 
HPLC trace of the isolated standard is given in Figure 3-3.  
 
 
Scheme 3-6: Synthesis of bis(2-ethylhexyl) 4-fluorophthalate. 
 
Figure 3-3: HPLC trace of 4-fluoro-bis(2-ethylhexy)phthalate. 
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3.5 Conclusion 
 Bis(2-ethylhexyl) phthalate is a widely used plasticizer found in a number of 
everyday household PVC items.  It is also widely used in medical tubing, blood storage 
bags, disposable medical examination gloves, surgical gloves, and dialysis tubing.2 Bis(2-
ethylhexyl) phthalate has also been reported to be used in non-plasticizer manners as 
well.  
DEHP is metabolized to the corresponding monoester, MEHP, which can then 
undergo further hydrolysis to yield phthalic acid or oxidation to give several oxidized 
metabolites (Figure 3-1).  Some studies show that the metabolites of DEHP may be the 
cause of some associated health concerns. However, due to the rapid metabolism and 
elimination of DEHP and its metabolites, long-term exposure is minimized reducing any 
potential hazards.  In most of the metabolism and distribution studies mentioned above, 
most, if not all, of the administered dose was accounted for in one form or another.  This 
leaves little evidence of long-term binding to target receptors.   
 Studies have shown that DEHP exposure is associated with a number of health 
concerns, especially in males.  The testes have shown to be a target organ for MEHP, 
resulting in a number of component malformations and sperm DNA damage. The reason 
behind why males are more at risk for health effects caused by DEHP exposure is 
unclear. Nonetheless, DEHP studies in female rodents have reported reproductive 
complications, such as decrease fertility. The main health concern that could be of 
heightened risk would be the inhalation of DEHP during mechanical ventilation, 
especially in premature infants.  This can sometimes be a prolonged procedure. Evidence 
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has proved to be directly correlated inhaled DEHP to insufficient production of surfactant 
in the lungs of premature infants. Other medical exposures to DEHP, like blood 
transfusions, have the capacity to be metabolized more quickly. 
 The goal of this project was to prepare the bis(2-ethylhexyl) phthalate 
diaryliodonium triflate aslt as a precursor for radio-fluorination to yield bis(2-
ethylhexyl)-[18F]-4-fluorophthalate. The radiotracer could then be injected into a test 
subject then undergo PET scans to analyze the short-term biodistribution of the 
compound at any given time point.  This imaging technique has the ability to overcome 
current limitations of classical analytical methods for measuring biodistribution. 
3.6 Experimental Data 
 
Bis(2-ethylhexyl) 4-iodophthalate  
This compound was esterified following the method of Kelber.51 In an oven dried 
Schlenk tube in a N2 charged atmosphere, 4-iodophthalic acid (5.0 g, 17 mmol) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) (5.10 mL, 34.2 mmol) was dissolved in 100 mL 
of dry CH3CN. To this solution, 2-ethylhexyl bromide (10.8 mL, 51.4 mmol) was added 
dropwise. The reaction vessel was sealed and heated at 95 °C for 14 hrs. The solvent was 
removed under high dynamic vacuum and the reaction mixture was washed with DI 
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water (100 mL) and extracted with ethyl acetate (4 X 100 mL). The organic layer was 
washed with DI water  (1 X 100 mL), then the ethyl acetate was dried over sodium 
sulfate, gravity filtered, and the solvent was removed from the product. Bis(2-ethylhexyl) 
4-iodophthalate was isolated by column chromatography with a gradient of 100 % 
hexanes to 5% EtOAc: hexanes. This yielded a pale yellow oil (5.45 g) in a 62% yield. 1H 
NMR (CD3CN, 300 MHz, 25°C) δ 8.01 (d, J= 1.2, 1H), 7.93 (dd, J1= 1.5, J2= 8.1, 1H), 
7.46 (d, J= 8.4, 1H), 4.16 (d, J= 5.7), 4H), 1.66-1.62 (m, 2H), 1.42-1.30 (m, 17H), 0.92-
0.87 (m, 13H); 13C NMR (CD3CN, 75 MHz, 25°C) δ 167.8, 167.1, 141.3, 138.4, 135.2, 
132.5, 131.5, 98.1, 69.2, 69.0, 39.7, 39.7, 31.2, 31.2, 29.8, 29.7, 24.6, 24.6, 23.8, 14.4, 
11.4. HRMS (ESI): Cald C24H37IO4 [M+Na]+: 539.1634, found: 539.1623.  
 
 
[3,4-Bis(((2-ethylhexyl)oxy)carbonyl)phenyl]-(4’-methoxyphenyl)iodonium triflate 
In an N2 charged glove box, in an oven dried Schlenk tube, bis(2-ethylhexyl) 4-
iodophthalate was dissolved in approximately 100 mL of dry acetonitrile. In an oven 
dried round bottom flask, Selectfluor (4.46 g, 12.6 mmol) was dissolved in 100 mL of 
dry acetonitrile. Trimethylsilyl acetate (TMS-OAc) (3.80 mL, 25.2 mmol) was slowly 
added via syringe. This mixture was allowed to stir for 3-5 mins, and added drop-wise to 
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the reaction mixture.  The reaction vessel was sealed and heated to 60 °C for 24 hrs. 
Potassium trifluoro(4-methoxyphenyl)borate (2.07 g, 9.68 mmol) was added to the 
reaction mixture. Trimethylsilyl triflate (TMS-OTf) (1.7 mL, 9.2 mmol) was diluted in 
dry acetonitrile (5 mL) and added in a drop-wise fashion to the reaction tube.  This 
mixture was allowed to stir at room temperature for 1 hour. The solvent was removed 
under high dynamic vacuum and the reaction mixture was washed with DI water (100 
mL) and extracted with dichloromethane (4 X 50 mL). The organic layer was dried over 
sodium sulfate and the solvent was removed in vacuo, leaving 3.42 g of a light pink paste 
in a 46% yield. 1H NMR (CD3CN, 300 MHz, 25°C) δ 8.27 (d, J= 1.8, 1H), 8.20 (dd, J1= 
1.8, J2= 8.4, 1H), 8.05 (d, J= 9.0, 2H), 7.76 (d, J= 8.4, 1H), 7.08 (d, J= 9.3, 2H), 4.20 (d, 
J= 5.4, 2H), 4.19 (d, J= 5.7, 2H), 3.851 (s, 3H), 1.67-1,603 (m, 2H), 1.39-1.30 (m, 17H), 
0.92-0.87 (m, 13H); 13C NMR (CD3CN, 75 MHz, 25°C) δ 167.1, 165.9, 164.7, 139.3, 
138.5, 137.3, 135.6, 135.6, 135.5, 132.9, 119.4, 116.7, 102.3, 69.6, 69.6, 56.9, 39.6, 31.2, 
31.1, 29.7, 24.6, 24.5, 23.7, 14.4, 14.4, 11.4; 19F NMR (CD3CN, 282 MHz, 25°C) δ -
79.29; HRMS (ESI): Cald C32H44F3IO8S [M-OTf]+: 623.2234 found: 623.2219.  
 
 
4-fluorophthalic acid 
This is a known compound (CAS 320-97-8) but was prepared following the methods of  
Dudič.34 In a 250 mL round bottom flask, 4-fluoro-o-xylene (2.0 mL, 16 mmol) was 
mixed with potassium permanganate (30.54 g, 193.3 mmol), pyridine (32 mL, 16 mmol) 
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and deionized water (32.0 mL) and refluxed for 48 hrs. After the mixture cooled to RT, 
the reduced manganese salts were removed by filtration, and the filtrate was acidified 
carefully with concentrated hydrochloric acid to pH 1-2. Extraction of the reaction 
mixture with ethyl acetate followed by evaporation of the solvent in vacuo produced a 
colorless solid. The crude product was dissolved in a minimal amount of ethyl acetate 
and stirred while hexanes was added to the mixture drop-wise. A white precipitate 
formed and was dried under high dynamic vacuum yielding 1.52 g (51%) of the pure 
product as a colorless solid. 1H NMR (CD3CN, 300 MHz, 25°C) δ 9.13 (s, 2H), 7.85 (dd, 
3JH-H= 8.5 Hz, 4JH-F= 5.4 Hz, 1H), 7.44 (dd, 3JH-F= 8.5 Hz, 4JH-H= 2.6 Hz, 1H), 7.32 (td, 
3JH-F= 8.6 Hz, 3JH-H= 8.6 Hz, 4JH-H= 2.6 Hz, 1H); 13C NMR (CD3CN, 75 MHz, 25°C) δ 
168.4, 168.211, 165.0 (d, 1JC-F= 251 Hz), 136.56 (d, 3JC-F= 8.2 Hz) 133.24 (d, 3JC-F= 9.2 
Hz) 128.29 (d, 4JC-F= 3.4 Hz), 118.96 (d, 2JC-F= 21.9 Hz) 117.00 (d, 2JC-F= 24.4 Hz); 19F 
NMR (CD3CN, 282 MHz, 25°C) δ 108.53 (td, 3JH-F= 8.6 Hz, 4JH-F= 5.4 Hz); HRMS (EI): 
Cald C8H5FO4 [M]+: 184.0172  found: 184.0175.  
 
 
Bis(2-ethylhexyl) 4-fluorophthalate 
This compound was esterified following the method of Kelber.51 Under inert atmosphere, 
in a 100 mL Schlenk tube, 4-fluorophthalic acid (1.01 g, 5.43 mmol) and 1,8-
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diazabicyclo[5.4.0]undec-7-ene (DBU) (1.6 mL, 11 mmol) were dissolved in dry 
acetonitrile (32 mL). 1-Bromo-2-ethylhexane (3.5 mL, 16 mmol) was added drop-wise to 
the solution. The reaction vessel was sealed and heated to 95 °C for 24 hrs. The solvent 
was removed and the resulting orange oil was treated with deionized water (50 mL) and 
extracted with ethyl acetate (3 X mL). Ethyl acetate was removed under reduced pressure 
and the product was isolated by column chromatography (95%hexanes: 5% ethyl 
acetate). The product obtained was 0.76 g of a colorless oil (34% yield). 1H NMR 
(CD3CN, 300 MHz, 25°C) δ 7.80 (dd, 3JH-H= 8.6 Hz, 4JH-F= 5.4 Hz, 1H), 7.39 (dd, 3JH-F= 
8.8Hz, 4JH-H= 2.6 Hz, 1H), 7.32 (td, 3JH-H= 8.4, 3JH-F= 8.4 Hz, 4JH-H= 2.6 Hz, 1H),  4.18 
(m, 4H), 1.65 (m, 2H), 1.34 (m, 17H), 0.90 (m, 13H); 13C NMR (CD3CN, 75 MHz, 25°C) 
δ 167.5 (d, 4JC-F= 2.3 Hz), 167.2, 164.8 (d, 1JC-F= 251 Hz), 136.7 (d, 3JC-F= 8.1 Hz) 132.8 
(d, 3JC-F= 9.0 Hz), 129.0 (d, 4JC-F= 3.4 Hz) 118.9 (d, 2JC-F= 21.9 Hz) 116.8 (d, 2JC-F= 24.3 
Hz) 69.2, 68.9, 39.7, 39.7, 31.2, 31.2, 29.8, 24.6, 24.6, 23.8, 14.5, 11.4; 19F NMR 
(CD3CN, 75.5 MHz, 25°C) δ -108.8 (td, 3JH-F= 8.4 Hz,  4JH-F= 5.2 Hz); HRMS (ESI): 
Cald C24H37FNaO4 [M+Na]+: 431.2574 found: 431.2570 
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CHAPTER 4 
Bisphenol A 
4.1 Introduction 
 Bisphenol A (BPA) is a commodity chemical used primarily as a polymer 
backbone component in polycarbonate plastics and epoxide resins, a class of polymers 
found in food and drink packaging, food can liners, bottle tops, water bottles, water 
supply pipes, and flame-retardants.  BPA is also used in the processing of PVC plastics, 
the recycling of thermal paper, in infant feeding bottles, and in microwave ovenware.4, 53 
Exposure to BPA mainly occurs orally.  Other exposure routes include inhalation and 
skin absorption. It has been shown that young children and infants are exposed to the 
highest doses of BPA.53 BPA has been known to migrate to the surface of plastic or resin 
containing products and leach into liquids and foods, including infant formulas.1 
 Low levels of BPA ranging from 2-8 µg/L can be found in the environment from 
the release of effluent from wastewater treatment plants. Bisphenol A dust particulates 
are typically well-contained in workplaces reducing the release of air-born BPA into the 
environment.  BPA has an aqueous solubility ranging from 0.120-0.300 g/L and this value 
can increase when in alkaline environments.54 
There are several health concerns associated with BPA that will be discussed in 
Section 4.3. Analyses have quantified the amount of BPA that the general public is 
exposed to through urine, serum, and tissue samples. BPA is suspected as being an 
endocrine disruptor, but the mechanism by which this could occur is unclear. 
The focus of this project was related to the projects described in the two previous 
chapters: to synthesize a bisphenol A diaryliodonium triflate precursor for the efficient 
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preparation of 18F-labelled BPA. From here the [18F] labeled analogue can be injected 
into a test subject to visualize the biodistribution of the compound in real-time, on a 
single subject, at multiple time points.  Based on preliminary data, 18F-BPA also shows 
potential as biomarker for liver function, since it undergoes rapid clearance and is 
subjected to enterohepatic recirculation. Once 18F-BPA is efficiently synthesized, its use 
as a probe to assess liver function and damage will be explored.   
 
4.2 Known Metabolism of Bisphenol A 
The metabolism of BPA mainly occurs in the gut and liver where the major 
metabolite, glucuronidated BPA is observed.  Other minor metabolites, sulfonated-BPA, 
and the ortho-quinone of BPA, have also been observed.55 These metabolites are shown 
in Figure 4-1. BPA is extensively absorbed in the gastrointestinal tract, then 
glucuronidated in the liver and gut in rats and mice, which limits the internal exposure to 
the aglycone form, which is the form suspected of being an endocrine disruptor.  In 
rodents, enterohepatic recirculation of the glucuronidated BPA occurs, which prolongs 
the serum lifetime of the compound. 
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Figure 4-1: Observed BPA metabolites. 
 
The enzymes responsible for the glucuronidation of BPA include a number of 
uridine diphosphate glucuronosyltransferase isoforms, which are located in the 
endoplasmic reticulum in vertebrates.  The major isoform responsible for the 
glucuronidation of BPA in the human liver is 2B15. Human, rat and mouse hepatocytes, 
along with microsomes from rat and human liver and intestine have been shown to 
catalyze the conversion of BPA to its glucuronidated conjugate. Sulfonation of BPA is 
catalyzed by sulfotransferase isoforms 1A1, 2A1 and 1E1.55 Evidence show that most of 
these enzymes are present in very low concentrations, or even absent altogether, in 
prenatal and perinatal humans.55, 56 The BPA-o-quinone is generated by a cytochrome 
P450 isoform, 1B1.56, 57 Hydroxylation of BPA yields 3-hydroxybisphenol A, which is 
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oxidized to the ortho-quinone (BPAQ).  This metabolite is suspected to be genotoxic. In 
2012, Kolsek and co-workers studied the reaction of BPAQ with deoxyadenosine and 
glutathione to elucidate the mechanism by which BPAQ interacts with DNA.57 It was 
determined that BPAQ reacts preferentially with guanine sites of DNA. It will also act as 
an electrophile toward glutathione if it is available, contributing to glutathione depletion 
in cells. Edmonds and co-workers performed a similar study in 2004 in which herring 
testes DNA and deoxyguanosine in aqueous buffer (pH 7) were treated with BPAQ 
resulting in a BPAQ-guanine-N7 adduct. It was suggested that metabolic oxidation of 
BPA could be as effective as estrogen oxidation in the generation of ortho-quinones that 
covalently bind to DNA.59 
In a study conducted by Yoo in 200160 female rats were administered 100 µg/kg 
of BPA intravenously, and rapid elimination of the aglycone form was observed. The 
half-life of BPA was determined to be 0.66 hours. In 2010, Doerge and co-workers 
administered 0-200 µg/kg of BPA orally and observed linear pharmacokinetics, 
enterohepatic recirculation of the conjugated BPA form, but not the aglycone form. There 
was also a significant inverse relationship observed between postnatal age and measures 
of internal exposure to aglycone BPA in rats with the elimination half-time decreasing 
with postnatal age. Measurements of the BPA analogues from urine, serum and feces 
were examined by LC/MS/MS.  Doerge also concluded that oral exposure of BPA to rats 
attenuates internal exposure to aglycone BPA to below 1% of the total administered 
dose.60 These findings highlight the significant differences between the elimination of 
BPA in rats by biliary secretion compared to non-human primates and humans, which 
eliminate BPA primarily in urine.  This study also noted that the maximum concentration 
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of algycone BPA in neonatal and adult rats from a one-time dose of 100 µg/kg, was 
found to be 0.4 nM-30 nM. When comparing oral and intravenous administration, Doerge 
noted that orally administered BPA resulted in a much lower percentage of algycone 
BPA (5% of dose) than intravenously administered BPA (45%). 
Another study monitored and compared the biodistribution of orally and 
intravenously administered 14C-labeled BPA in rats at doses of 100 or 0.1 mg/kg.  It was 
determined that the 14C-BPA derived radioactivity was tightly bound to plasma protein 
and preferentially distributed to the plasma with a blood/plasma ratio of 0.67.  This study 
also reported finding free BPA in feces.62 The author conducted a similar study using 
Cynomolgus monkeys in 2002. The monkeys were subjected to a single oral or 
intravenous dose of 14C-BPA (100 µg/kg). It was reported that 79-85% of the dose was 
excreted in the urine over 7 days, with most of the urinary excretion recovered after the 
first 24 hours after administration.  Radioactivity measured in fecal matter only 
accounted for 1.8-3.1% of the total radioactive dose. The unchanged 14C-BPA half-life 
was somewhat shorter for male monkeys (t1/2= 0.57 hr) than that for females (t1/2= 0.39 
hr). The authors concluded from these studies that the aglycone form was fractionated 
into adipose tissue after intravenous injection, and 14C-BPA derived radioactivity also 
bound tightly to plasma protein.63 For these studies, radioactivity was determined by 
liquid scintillation counting and the identification and quantification of metabolites were 
determined by HPLC analysis.  
 
 
 
72 
 
4.3 Potential Health Effects of Bisphenol A 
A large amount of data have been generated on the potential toxic effects of BPA, 
and a number of reproductive and developmental effects have been associated with 
exposure to this compound. While, BPA is typically described as being “weakly” 
estrogenic, a number of studies indicate a number of additional biological activities.53 Xin 
and co-workers conducted a study in which they treated INS-1 cells with various doses of 
BPA (0, 25, 50 or 100 µM) and assessed subsequent DNA damage by nuclear comet 
assays, gel electrophoresis, and western blot analysis.  The results indicated that BPA is 
associated with a dose-dependent increase in DNA strand breaks at higher doses and with 
greater DNA migration from the nucleus into the comet tail. DNA damage was also 
suggested by the observation of a significant increase in the expression of DNA repairing 
proteins.64  
Three epidemiological studies in humans reported associations with high urinary 
BPA metabolite concentrations and reduced semen quality.4 A study conducted on 
factory workers in China found that those who worked with BPA were found to have 
reduced sperm count and decreased sperm concentration. A 2010 study on fertile males in 
the US determined that there was an inverse relationship with BPA urine concentration 
and sperm count and motility of sperm. A third study conducted on infertile males also 
concluded that there was an inverse relationship with urinary BPA concentration and 
sperm count and sperm motility. This study also reported that there was also a positive 
correlation with abnormal sperm morphology.  
BPA exposure has been correlated with a number of cardiovascular and neuronal 
disorders. Michaela and co-workers investigated the effects of BPA on T-type calcium 
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channels, which are vital regulatory elements in both the cardiovascular and neuronal 
systems.  The whole-cell patch clamp technique was used to measure calcium current 
through T-type calcium channels expressed in HEK 293 cells. It was found that BPA 
inhibited the current through calcium channel subtypes in a concentration-dependent 
manner. The concentration range resulted in a physiological response that corresponds to 
that found in human fluids.65 
There has been some correlation between BPA exposure and a decrease in 
glucose metabolism.  In 2013, Zhang and co-workers, studied the effects of BPA on 
glucose metabolism and adipokine expression in female offspring of pregnant rats that 
had been exposed to BPA. Pregnant rats were exposed to aqueous BPA at doses of either 
1 µg/mL or 10 µg/mL from the sixth day of gestation to the end of the lactation period.  
Body weight, fasting serum glucose levels, insulin, adiponectin (ADP) (adipokine needed 
for glucose metabolism), Zinc-alpha2-glycoprotein (ZAG) (body weight regulator), ADP 
mRNA, and protein expression from the adipose tissue of 7 week old female offspring 
were examined.  It was observed that the female offspring had higher body weight, 
significantly higher serum glucose and insulin levels, lower serum ADP and plasma ZAG 
protein levels, and lower ADP and ZAG mRNA and protein expression as compared to 
the control group.  It was concluded that BPA exposure during early development has 
long-term effects on body weight and glucose metabolism in rats.66 
A study of BPA exposure in pregnant rats being exposed to BPA revealed similar 
results as Zhang’s work. In 2010, Alonso-Magdalena and co-workers treated pregnant 
rats with 10 or 100 µg/kg/day during day 9-16 of gestation.67 Glucose tests performed on 
both the mother and offspring divulged that BPA aggravated the insulin resistance 
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produced during pregnancy, increased plasma insulin, triglycerides, and leptin 
concentrations in comparison to controls.  Six-month old male offspring exposed to BPA 
in utero expressed decreased glucose tolerance increased insulin resistance and altered 
blood parameters. As a result, the authors of the study suggested that BPA exposure may 
be linked to an increased risk of diabetes. 
In 2014, Khalil and co-workers investigated whether BPA is correlated with 
obesity and metabolic changes in human liver.68 A cross-sectional study was conducted 
on 39 obese and overweight children (3-8 years old) indicated that a higher BPA 
concentration in overweight children was associated with an increase in free thyroxine 
levels. In male candidates, there was a correlation of serum BPA (1.82 µg/g) and elevated 
levels of the liver enzyme aspartate aminotransferase, elevated diastolic blood pressure, 
and insulin resistance. 
A 2014 study showed that colorectal cancer SW480 cells exposed to nanomolar to 
micromolar concentrations of BPA (10-8 M and 10-5 M) exhibited changes in the 
expression of more than 56 proteins relevant to structure, motility, cell proliferation, 
production of ATP, oxidative stress, and protein metabolism.  It was also suggested that 
BPA increased migration and invasion of cancer cells, as well as triggered 
transformations from epithelial to mesenchymal transitions of colorectal cancer cells.69 
There is a substantial body of work indicating that BPA is an endocrine disruptor, 
but the mechanism by which BPA could function in such a capacity in unclear.  BPA’s 
estrogenic activity is weak; its binding affinity to ER-alpha and ER-beta are more than 
10,000 times lower than that of estradiol. However, as the above studies show, cellular 
responses are induced by very low concentrations of BPA. In a study in which pregnant 
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rats were fed 0.025 µg/kg/day and 0.25 µg/kg/day, masculinization of a brain region 
essential for cyclic gonadotropin release in female offspring was observed. This suggests 
that BPA could have acted as an estrogen in specific areas of a developing brain that are 
important for sexual differentiation.70  
Vom Saal and Hughes reviewed several low dose rodent BPA studies in 2005. 
Several health effects, including increased postnatal growth, early onset of sexual 
maturity in females, altered plasma luteinizing hormone levels, an increase in prostate 
size in male offspring, and stimulation of mammary gland development in female 
offspring were observed.  Other health effects included increased mortality of embryos, 
altered immune function, increase in progesterone receptor mRNA levels, modulation of 
somatostatin receptors in the brain, and behavioral changes such as hyperactivity, an 
increase in aggressiveness, altered reactivity to pain, and impaired learning.71 
 
4.4 Preliminary Data and Synthetic Short Comings 
Preliminary studies conducted in the DiMagno lab focused on the routes relying 
on the dimethylether protected BPA derivative.  The synthesis of the diaryliodonium salt, 
which was developed by Dr. Kiel Neumann, relied heavily upon a selective iodoarylation 
method that was recently published by our research group.72 A synthetic shortcoming of 
using a diaryliodonium salt precursor, featuring methyl ether protective groups, was that 
aggressive deprotection conditions were required, involving the use of a strong acid. 
These conditions led to destruction of the parent molecule, perhaps by aryl ring 
protonation and the generation of a stabilized cumyl cation.  The radio-fluorination and 
deprotection procedure that Dr. Neumann developed is shown in Scheme 4-1. While the 
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deprotection conditions used in this synthesis provided radio-fluorinated BPA, BBr3 
proved to be aggressive toward the radiosynthesis equipment and the yields were quite 
low. To pursue imaging studies with 18F-BPA, a better synthesis was needed. It was 
proposed that a more acid-labile phenol-protecting group be used.  We selected ethoxy 
methyl (EOM) as a more acid-labile alternative to methyl ether. Chloromethyl ethyl ether 
is preferred over other acid-labile protecting groups, like methoxy methyl (MOM), 
because it is less volatile and thus, less hazardous to work with. 
   
 
Scheme 4-1: Radiosynthetic route of [18F] FBPA. 
 
Dr. Neumann’s preliminary PET imaging data of [18F] BPA in mice suggests that 
BPA has promising potential as a biomarker for liver function. The PET scan of a 
healthy mouse can be seen in Figure 4-2. This is a PET scan taken 60 minutes post-
intravenous injection.  These data show that the most concentrated areas of radioactivity 
are in the stomach and intestines. This is indicative of rapid metabolism and clearance of 
the radiolabelled compound from the bloodstream.  In Figure 4-3, it is shown that at 10 
minutes and 22 minutes post injection, there is a spike in radioactivity in the intestine 
followed by a slight decrease. This is indicative of enterohepatic recirculation occurring.  
The highest concentration of radioactivity in the intestine was at approximately 53 
 minutes. This suggested rapid metabolism of the majority of the radioactive compound.  
No data was acquired on rate or amount of radioactivity excreted during this experiment.  
At 55 minutes the mouse was sacrificed and each organ was weighed and
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4.5 Synthetic Approach 
 I explored several synthetic routes 
(ethoxymethoxy)phenyl)propan
trifluoromethanesulfonate
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commercially available bisphenol A was protected with chloromethyl ethyl ether. Next, I 
conducted a heteroatom-directed ortho-lithiation, followed by transmetalation with 
trimethyl borate. The obtained aryl borate was treated with potassium bifluoride to 
hydrolyze the borate esters and form the corresponding potassium trifluoroborate. 
However, lithiation was not efficient and the desired product was only obtained in 8% 
yield. Nonetheless, this compound was carried forward.  Coupling with 
bis(acetoxy)iodoanisole took place in excellent yields.  However, because the 
trifluoroborate derivative was formed in such poor yields, other avenues toward the 
synthesis were explored. 
 
Scheme 4-2: First synthetic route attempted to form a BPA diaryliodonium salt. 
 
 Several iodination reactions were employed to find a suitable method to 
selectively iodinate 4,4'-(propane-2,2-diyl)bis((ethoxymethoxy)benzene). Because of the 
symmetrical nature of this compound, selective, mono-substitution was not achieved 
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when using I2 and TMSI as iodinating agents under the conditions shown in Scheme 4-3. 
 
Scheme 4-3: Iodination methods investigated for 4,4'-(propane-2,2- 
diyl)bis((ethoxymethoxy)benzene). 
 
Because the bulky triisopropylsilyl (TIPS) protecting group has been shown to 
inhibit ortho halogenation in heterocyclic systems,73 I thought that preparation of a 
selectively protected BPA derivative, in which only one phenolic oxygen was silylated, 
might allow for selective iodination. Mono-TIPS substituted BPA was subjected to 
several iodination methods using I2 and NIS as the iodine source (Scheme 4-4) but a 
mixture of iodinated isomers were observed in each case.  
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Scheme 4-4: Attempted selective iodination of mono-substituted TIPS BPA. 
 
Iodoarylation was also attempted with 4-methoxyphenyl iodonium diacetate in the 
presence of 1-(chloromethyl)-1,4-diazabicyclo[2.2.2]octan-1-ium 
hexafluorophosphate(V), which acts as a weak base to scavenge any acid that could be 
potentially generated. (Scheme 4-5). Activation of 4-methoxyphenyl iodonium diacetate 
with TMS-TFA gave no reaction. Even after 24 hour at 40°C, there was no conversion. 
When TMS-OMS was used as the catalyst, there was an instant color change to light 
green and the NMR data from time = 15 minutes indicated complete conversion of 
ArI(OAc)2 to ArI and no production of the desired diaryliodonium salt.  The result was 
the same when TMS-OTf was used, but the color change was from clear to brown.   It 
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was thought that 1-(chloromethyl)-1,4-diazabicyclo[2.2.2]octan-1-ium 
hexafluorophosphate(V) could have potentially been interacting with the TMS-X groups 
or the bis(acetoxy) iodoanisole, so the reaction was attempted without the base. This 
reaction resulted in decomposition of the I(III) center to I(I) but no noticeable sign of 
deprotection.   
 
              
Scheme 4-5: Attempted iodoarylation of 4,4'-(propane-2,2-
diyl)bis((ethoxymethoxy)benzene), with various TMS-X groups in the presence of 1-
(chloromethyl)-1,4-diazabicyclo[2.2.2]octan-1-ium hexafluorophosphate(V).  
 
In the end, we elected to perform the initial iodination on a dimethyl ether 
protected derivative of BPA using chemistry developed by Dr. Neumann. 72 Once the 
selectively iodinated, the compound was deprotected with BBr3 and protected with 
chloromethyl ethyl ether and the iodine center was oxidized with Selectfluor. Coupling 
of the aryliodonium diacetate with potassium trifluoro(4-methoxyphenyl)borate gave the 
corresponding diaryliodonium salt (Scheme 4-6). The only major difficulty encountered 
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in this synthesis was discovering the optimal recrystallization conditions for the 
diaryliodonium triflate salt. 
 
 
 
Scheme 4-6: Total synthesis of 
(2-(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)phenyl)(4-
methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate. 
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4.6 Conclusions 
 In summary, bisphenol A is a widely used industrial compound found in a number 
of everyday consumer products. BPA is metabolized primarily in the gut and liver where 
the major metabolite is the guluronidated conjugated and minor metabolites include 
sulfonated-BPA and the 3,4-quinone-BPA.  BPA and its metabolites have been 
associated with several health effects including damage to sperm DNA and morphology, 
cardiovascular and neuronal disorders, obesity, insulin resistance, and altered glucose 
metabolism, high blood pressure, and was reported to accelerate the invasion and 
metastasis of colorectal cancer cells.  BPA was also shown to act as an estrogen in 
specific areas of the brain responsible for sexual differentiation. It was also associated 
with an early onset of sexual maturity in female rats, increased prostate size in male rats, 
and altered immune function and behavioral changes.   
Preliminary data generated by Dr. Kiel Neumann suggests that BPA has great 
potential as a biomarker for liver function.  Most importantly, it suggests that BPA is 
cleared remarkably fast and does not bind to any target receptor with high affinity in 
mice.  While the synthetic methods used to generate [18F] FBPA were successful, the 
deprotection conditions with BBr3 proved to be harsh toward the radiosynthesis 
equipment. This research was designed to synthesize a BPA diaryliodnium salt precursor 
with a more acid-labile protecting group. The synthesis of this precursor will allow for 
late-stage radio-fluorination and application to the monitoring of biodistribution of BPA 
in animal models with both healthy and damaged livers and visualize liver function. 
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4.7 Experimental Data 
 
 
4,4'-(propane-2,2-diyl)bis(methoxybenzene)  
This compound is known (CAS 1568-83-3) and the synthesis was modeled after the 
methods of Kubo.75 In an oven dried, Schlenk tube, with a magnetic stir bar, under a N2 
atmosphere, 4,4'-(propane-2,2-diyl)diphenol (3.00 g; 13.1 mmol) was dissolved in 25 mL 
of dry THF and  this solution was cooled to 0 °C.  Sodium hydride (0.95 g; 39.4 mmol) 
was added slowly and this mixture was stirred at 0 °C for 30 mins. Methyl iodide (2.3 
mL; 53 mmol) was added dropwise to the reaction mixture at 0 °C. The tube was sealed, 
transferred to an oil bath and heated at 75 °C overnight.  The reaction was monitored by 
TLC with an elution of 30% ethyl acetate in hexanes and gave an Rf value of 0.79. The 
reaction was cooled to RT then quenched with DI H2O. The solvent was removed in 
vacuo then the product was extracted with dichloromethane (3 X 25 mL).  The organic 
layer was dried over sodium sulfate, gravity filtered, and evaporated to yield a colorless 
solid.  Any residual starting material was removed by dissolving it in hexanes (with 
sonication) and filtering the remaining solid. The solvent was removed from the filtrate, 
yielding 2.78 g (82.4% yield) of colorless, prism-like crystals. 1H NMR (CD3CN, 400 
MHz, 25°C) δ 7.15 (d, J=8.6 Hz, 4H), 6.82 (d, J=8.6 Hz, 4H), 3.74 (s, 6H), 1.62 (s, 6H); 
13C NMR (CD3CN, 100 MHz, 25°C) δ 158.6, 144.1, 128.7, 114.3, 55.8, 42.3, 31.4; 
HRMS (EI): calcd for C17H21O2 [M+H]+: 257.1542; found 257.1543. 
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2,2,2-trifluoro-1-((2-methoxy-5-(2-(4-methoxyphenyl)propan-2-yl)phenyl)(4-
methoxyphenyl)-3-iodanyl)ethan-1-one  
This compound was synthesized following the procedure reported by Hu.76 In a N2 
charged glove box, in an oven dried Schlenk flask, 4,4'-(propane-2,2-
diyl)bis(methoxybenzene) (6.01 g; 23.5 mmol) was dissolved in 50 mL of dry 
acetonitrile.  In dry acetonitrile (50 mL) (4-methoxyphenyl)-3-iodanediyl diacetate 
(3.30 g; 9.38 mmol) was added to the reaction flask. In a scintillation vial, trimethylsilyl 
trifluoro acetate (3.2 mL; 19 mmol) was diluted in dry acetonitrile (50 mL).  This 
solution was then added slowly to the reaction mixture. The flask was sealed and stirred 
at 80 °C for 24 hrs.  The solvent was removed under high dynamic vacuum. A small 
amount of ethyl acetate was added to the resulting orange viscous oil and subjected to 
sonication. Methyl-tert-butyl ether (100 mL) was added to the flask and subjected to 
sonication for 20 mins. A colorless solid was precipitated out of the solution. The 
solution was decanted off into a round bottom flask and the volume was reduced by 10% 
forming more solid precipitate. The solid was dried under high dynamic vacuum giving 
3.48 g (63%) of the desired product. 1H NMR (CD3CN, 300 MHz, 25°C) δ 7.88 (d, J=9.2 
Hz, 2H), 7.67 (d, J=2.3 Hz, 1H), 7.430, (dd, J1=8.7 Hz, J2=2.3 Hz, 1H), 7.08 (d, J=2.2 Hz, 
2H), 7.05 (d, J=8.6, Hz 1H), 6.95 (d, J=9.3 Hz, 2H), 6.80 (d, J=8.7 Hz, 2H), 3.89 (s, 3H), 
3.83 (s, 3H), 3.76 (s, 3H), 1.60 (s, 6H); 13C NMR (CD3CN, 75 MHz, 25°C) δ 163.6, 
158.8, 155.6, 147.9, 142.6, 138.5, 135.0, 133.6, 128.6, 114.4, 113.1, 106.6, 103.9, 57.9, 
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56.6, 55.9, 42.8, 30.9; 19F NMR (CD3CN, 282 MHZ, 25 °C), -75.48;  HRMS (HREI): 
Calcd for C26H26F3IO4 [M-TFA]+: 489.0938; found 489.0929. 
 
 
2-iodo-1-methoxy-4-(2-(4-methoxyphenyl)propan-2-yl)benzene 
This compound is known (CAS 1501940-95-9) and was prepared following the 
procedure of Hu.76 In a N2 charged atmosphere, in a Schlenk flask, 2,2,2-trifluoro-1-((2-
methoxy-5-(2-(4-methoxyphenyl)propan-2-yl)phenyl)(4-methoxyphenyl)-3-
iodanyl)ethan-1-one (3.51 g; 5.98 mmol) and sodium iodide (2.69 g; 17.9 mmol) were 
dissolved in dry acetonitrile (60 mL).  The Schlenk flask was sealed and stirred for 4 
hours at 120 °C. The flask was cooled to RT. The solvent was removed in vacuo and the 
compound was isolated by column chromatography (100 % hexanes). The Rf value for 
the desired product was 0.47. After removal of solvent, the product was 2.29 g of a pale 
yellow oil (96.8% yield). 1H NMR (CD3CN, 300 MHz, 25°C) δ 7.62 (d, J=2.4 Hz, 1H), 
7.23 (dd, J1=8.6 Hz, J2= 2.4 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 6.83 (d, J=8.7 Hz, 1H), 6.83 
(d, J=8.7 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 1.59 (s, 6H); 13C NMR (CD3CN, 75 MHz, 
25°C) δ 158.6, 157.0, 146.5, 143.3, 138.5, 128.9, 128.6, 114.3, 111.7, 86.0, 57.0, 55.8, 
42.1, 31.1. HRMS (HREI):  Calcd C17H19IO2 M+: 382.0430; found 382.0447.  
 
 
4-(2-(4-hydroxyphenyl)propan-2-yl)-2-iodophenol  
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This compound is known (CAS 88953-17-7) but was prepared by a different route. In a 
Schlenk tube with a magnetic stir bar that had been purged with nitrogen gas, 2-iodo-1-
methoxy-4-(2-(4-methoxyphenyl)propan-2-yl)benzene (2.22 g; 5.79 mmol) was dissolved 
in dry dichloromethane (20 mL) and cooled to 0 °C. An excess of boron tribromide (2.19 
mL; 23.2 mmol) was added drop-wise to the reaction mixture. The flask was sealed and 
stirred at 0 °C for 2 hrs. The solution was gently poured over 5 grams ice. The aqueous 
layer was washed with dichloromethane (3 X 20 mL), which was washed with pH 5 
deionized water (2 X 25mL).  The organic layer was dried over sodium sulfate, and the 
solvent was removed in vacuo yielding1.76 g (86%) of a colorless solid.  1H NMR 
(CD3CN, 400 MHz, 25°C) δ 7.2 (s, 1H), 7.07 (dd, J1=8.3 Hz, J2=2.3 Hz, 1H), 7.05 (d, 
J=8.6 Hz, 2H), 6.78 (d, J=8.4 Hz, 1H), 6.71 (s, 1H), 6.71 (d, J=8.6 Hz, 2H), 1.57 (s, 6H); 
13C NMR (CD3CN, 100 MHz, 25°C) δ 155.7, 154.7, 146.0, 142.6, 138.0, 129.1, 128.6, 
115.6, 115.4, 84.1, 42.1, 31.14. . HRMS (HREI): Calcd for C15H15IO2 M+: 354.0117, 
found 354.0126 
 
 
1-(ethoxymethoxy)-4-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)-2-iodobenzene   
In an oven-dried 25 mL Schlenk storage tube purged with nitrogen, 4-(2-(4-
hydroxyphenyl)propan-2-yl)-2-iodophenol (1.76 g; 4.96 mmol) was dissolved in dry THF 
(17 mL).  Hunig’s base (3.50 mL; 19.9 mmol) was added drop-wise to this solution, and 
the reaction mixture was stirred for 10 minutes and cooled to 0 °C followed by the drop-
wise addition of chloromethyl ethyl ether (1.50 mL; 19.9 mmol). The tube was sealed and 
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transferred to an oil bath to react at 40 °C for 48 hrs.  The solvent was removed in vacuo, 
and the product was extracted with dichloromethane (3 X 20 mL) from deionized water. 
The organic aliquots were combined and washed with an aqueous solution of NaHCO3 
(pH 8). The dichloromethane was dried over sodium sulfate, and the solvent was 
removed in vacuo. TLC was conducted in 10% ethyl acetate in hexanes, giving an Rf 
value of 0.52 for the desired product.  The product was isolated by column 
chromatography (10:90; ethyl acetate: hexanes) yielding 1.88 g (80.7%) of a pale yellow 
oil. 1H NMR (CD3CN, 400 MHz, 25°C) δ 7.67 (d, J=2.4 Hz, 1H), 7.19 (dd, J1=8.6 Hz, 
J2= 2.3 Hz, 1H), 7.16 (d, J= 8.6 Hz, 2H), 6.99 (d, J=8.8 Hz, 1H), 6.94 (d, J=8.8 Hz, 2H), 
5.23 (s, 2H), 5.18 (s, 2H), 3.72 (q, J=7.0, 2H), 3.69 (q, J=7.0, 2H), 1.61 (s, 6H), 1.17 (t, 
J=7.0, 6H); 13C (CD3CN, 100 MHz, 25°C) δ 156.2, 154.8, 147.2, 144.1, 138.2, 128.8, 
128.4, 116.6, 115.3, 94.56, 93.86, 87.66, 65.35, 64.77, 42.22, 31.19, 15.62, 15.66. HRMS 
(ESI): calcd for C21H27IO4 [M+Na]+: 493.0852, found 493.0834. 
 
 
 
(2-(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)phenyl)(4-
methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate 
 
In an N2 charged glove box, in an oven-dried 100 mL Schlenk tube, 1-(ethoxymethoxy)-
4-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)-2-iodobenzene (1.80 g; 3.82 mmol) was 
dissolved in 40 mL of dry CH3CN. 1-(chloromethyl)-1,4-diazabicyclo[2.2.2]octan-1-ium 
hexafluorophosphate(V), (0.58 g; 1.91 mmol) was added to the reaction flask. In a 
separate vial, Selectfluor (1.76 g; 4.97 mmol) was dissolved in 20 mL of dry CH3CN, 
90 
 
followed by the addition of trimethylsilyl acetate (1.50 mL; 9.95 mmol) in a drop-wise 
fashion. This mixture was shaken for 3-5 mins and slowly added to the reaction flask. 
The flask was sealed and allowed to stir at RT for 21 hrs. Potassium trifluoro(4-
methoxyphenyl)borate (0.64 g; 2.97 mmol) was dissolved in a small amount of dry 
CH3CN  followed by trimethylsilyl trifluoroacetate (0.33 mL; 1.93 mmol) diluted in 10 
mL of dry CH3CN was added to the reaction flask. This mixture was stirred at RT for 12 
hrs. The solvent was evaporated, leaving behind ~5-10 mL of CH3CN, which was poured 
into an aqueous solution of sodium acetate (basic pH). The product was extracted from 
the aqueous layer with dichloromethane (3 X 30 mL). The organic aliquots were 
combined and washed with deionized water (1 X 50 mL). The water layer was washed 
with dichloromethane again (2 X 30 mL). The organic aliquots were combined and dried 
over sodium sulfate. The solvent was removed in vacuo, yielding a brown, viscous oil, 
which was dissolved in hexanes (2 X 100 mL) and subjected to sonication. The hexanes 
solution was poured off of the oil. The oil was treated with methyl-tert-butyl ether with 
sonication. The solution was poured off and placed under high dynamic vacuum. This 
produced a tan colored foam. The solid was dissolved in a minimal amount of acetonitrile 
and transferred to a 1M solution of sodium trifluoromethane sulfonate (30 mL). This 
mixture stirred for 30 mins, and extracted with dichloromethane (3 X 30 mL), dried over 
sodium sulfate, gravity filtered, and then the solvent was removed under reduced 
pressure. To insure that all trifluoroacetate ions were exchanged with triflate ions, the 
orange product was passed through an ion exchange resin. The ion exchange column was 
loaded with Amberlite IRA-450 (Cl) and a mixture of acetonitrile/water (8:2 by volume). 
The solution was allowed to drain slowly. A 1.0 M solution (100 mL) of sodium triflate 
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was passed through the ion exchange resin very slowly (~1 drop/15 sec).  Dry 1-((2-
(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)phenyl)(4-
methoxyphenyl)-λ3-iodanyl)-2,2,2-trifluoroethan-1-one was dissolved in a solution of 
acetonitrile and water (8:2 by volume) and loaded onto the ion exchange resin. The 
solution was passed through the column very slowly at a rate of approximately 1 drop/ 30 
seconds and collected. The (2-(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-
2-yl)phenyl)(4-methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate solution was dried 
under reduced pressure overnight. The product was 1.48 g of a tan solid that was found in 
95 % purity (41 % yield).  1H NMR (CD3CN, 300 MHz, 25°C) δ 7.92 (d, J=9.2 Hz, 2H), 
7.69 (d, J=2.2 Hz, 1H), 7.47 (dd, J1=8.6 Hz, J2=2.2 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.09 
(d, J1=8.9 Hz, 2H), 7.01 (d, J1=9.1 Hz, 2H), 6.92 (d, J1=8.8 Hz, 2H), 5.35 (s, 2H), 5.20 (s, 
2H), 3.85 (s, 3H), 3.68 (q, J1=7.1 Hz, 2H), 3.62 (q, J1=7.1 Hz, 2H), 1.62 (s, 6H), 1.16 (t, 
J1=7.0 Hz, 3H), 1.11 (t, J1=7.0 Hz, 3H); 13C NMR (CD3CN, 75 MHz, 25°C) δ 164.3, 
156.6, 153.5, 149.1, 143.6, 139.0, 134.9, 134.3, 128.7, 119.0, 116.9, 116.1, 105.3, 100.9, 
95.2, 94.0, 66.1, 65.0, 56.8, 43.1, 30.8, 15.5, 15.4; 19F NMR (CD3CN, 282 MHz, 25°C) -
79.3; HRMS (LR-FAB): calcd for C29H34IO8S [M-OTf]+: 577.1451, found 577.1448 
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1H NMR Spectrum of bis(2-ethylhexyl) 4-iodophthalate  
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1H NMR Spectrum of bis(2-ethylhexyl) 4-iodosylphthalate compound with 1-methoxy-4-
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13C NMR Spectrum of bis(2-ethylhexyl) 4-iodosylphthalate compound with 1-methoxy-
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19F NMR Spectrum of bis(2-ethylhexyl) 4-iodosylphthalate compound with 1-methoxy-4-
((trifluoromethyl)sulfonyl)benzene (1:1) 
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13C NMR Spectrum of 4-fluorophthalic acid 
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19F NMR Spectrum of 4-fluorophthalic acid 
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1H NMR Spectrum of bis(2-ethylhexyl) 4-fluorophthalate 
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13C NMR Spectrum of bis(2-ethylhexyl) 4-fluorophthalate 
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19F NMR Spectrum of bis(2-ethylhexyl) 4-fluorophthalate 
 
 
114 
 
 
 
 
 
 
 
 
 
 
F
O
O
O
O
115 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR Spectrum of 4,4'-(propane-2,2-diyl)bis(methoxybenzene) 
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13C NMR Spectrum of 4,4'-(propane-2,2-diyl)bis(methoxybenzene) 
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1H NMR Spectrum of 2,2,2-trifluoro-1-((2-methoxy-5-(2-(4-methoxyphenyl)propan-2-
yl)phenyl)(4-methoxyphenyl)-3-iodanyl)ethan-1-one 
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13C NMR Spectrum of 2,2,2-trifluoro-1-((2-methoxy-5-(2-(4-methoxyphenyl)propan-2-
yl)phenyl)(4-methoxyphenyl)-3-iodanyl)ethan-1-one 
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19F NMR Spectrum of 2,2,2-trifluoro-1-((2-methoxy-5-(2-(4-methoxyphenyl)propan-2-
yl)phenyl)(4-methoxyphenyl)-3-iodanyl)ethan-1-one 
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1H NMR Spectrum of 2-iodo-1-methoxy-4-(2-(4-methoxyphenyl)propan-2-yl)benzene 
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13C NMR Spectrum of 2-iodo-1-methoxy-4-(2-(4-methoxyphenyl)propan-2-yl)benzene 
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1H NMR Spectrum of 4-(2-(4-hydroxyphenyl)propan-2-yl)-2-iodophenol 
 
 
O
O
I
130 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR Spectrum of 4-(2-(4-hydroxyphenyl)propan-2-yl)-2-iodophenol 
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1H NMR Spectrum of 1-(ethoxymethoxy)-4-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)-
2-iodobenzene 
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13C NMR Spectrum of 1-(ethoxymethoxy)-4-(2-(4-(ethoxymethoxy)phenyl)propan-2-yl)-
2-iodobenzene 
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1H NMR Spectrum of  (2-(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-2-
yl)phenyl)(4-methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate 
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13C NMR Spectrum of  (2-(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-2-
yl)phenyl)(4-methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate 
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19F NMR Spectrum of  (2-(ethoxymethoxy)-5-(2-(4-(ethoxymethoxy)phenyl)propan-2-
yl)phenyl)(4-methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate 
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